STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 113864

TO: Hong Liu
Location: REM-5C11
Art Unit: 1624
Wednesday, February 11, 2004

Case Serial Number: 10/075847

From: Peggy Ruppel
Location: Biotech-Chem Library
Phone: 571-272-2557
REM E01b65
peggy.ruppel@uspto.gov

Search Notes

Dear Examiner Liu:

Please see attached results. Barb O'Bryen supervised my work on this search as part of my training, so she did, indeed, work on this search.

Feel free to contact me if you have any questions.

Thank you for using STIC services

Peggy Ruppel
~~308-2278~~ 272-2557

=> b reg
FILE 'REGISTRY' ENTERED AT 11:27:54 ON 11 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2004 HIGHEST RN 648858-13-3
DICTIONARY FILE UPDATES: 10 FEB 2004 HIGHEST RN 648858-13-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que l50
L6 STR



This structure represents our parent compound for the search. The highlighted nodes and bond are designated as ring or chain throughout the following structures.

NODE ATTRIBUTES:
NSPEC IS RC AT 14
NSPEC IS RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L7 STR



NH~Ak
@16 17

Ak~N~Ak
18 @19 20

CH~Ak
@21 22

Ak~C~Ak
23 @24 25

CH~Ak~X
@26 27 28

Ak~C~Ak~X
29 @30 31 32

X~Ak~C~Ak~X
33 34 @35 36 37

VAR G1=21/24/26/30/35/CH2
VAR G2=16/19/NH2
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 17
CONNECT IS E1 RC AT 18
CONNECT IS E1 RC AT 20
CONNECT IS E1 RC AT 22
CONNECT IS E1 RC AT 23
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 29
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X4 C AT 17
ECOUNT IS M1-X4 C AT 18
ECOUNT IS M1-X4 C AT 20
ECOUNT IS M1-X4 C AT 22
ECOUNT IS M1-X4 C AT 23
ECOUNT IS M1-X4 C AT 25

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

Structures L7 and L8 are two general sub-structures of L6 and were used to narrow the search.

L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY SAT AT 14

Heterocycle at node 14 is monocyclic and unsaturated.

Searched by P. Ruppel

DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 14

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L9 (6520) SEA FILE=REGISTRY SSS FUL L6
L10 (747) SEA FILE=REGISTRY SUB=L9 SSS FUL (L6 AND (L7 OR L8))
L11 STR



structures L11-L14 were known to be unacceptable and were removed from the answerset.

(Cyclic groups off of phenyl/naphthyl groups)

NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 6

STEREO ATTRIBUTES: NONE
L12 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE
L13 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 1
NSPEC IS RC AT 2
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 6

STEREO ATTRIBUTES: NONE
L14 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE
L15 544 SEA FILE=REGISTRY SUB=L10 SSS FUL (L6 AND L14 NOT (L11 OR L12 OR L13))
L17 STR



this is a restatement of L6

NODE ATTRIBUTES:
NSPEC IS RC AT 14
NSPEC IS RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L20 STR

Structures L20, and L46-L48 were used to finalize the search



NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
CONNECT IS E2 RC AT 3
CONNECT IS E1 RC AT 5
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE
L46 STR



VAR G1=X/7/8/10/13/15/22/19/22/17/CN/NO2/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
CONNECT IS E1 RC AT 5
CONNECT IS E1 RC AT 7
CONNECT IS E1 RC AT 11
CONNECT IS E1 RC AT 12
CONNECT IS E1 RC AT 14
CONNECT IS E1 RC AT 16
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 23
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L47 STR



VAR G1=X/7/8/10/13/15/22/19/22/17/CN/NO2/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
CONNECT IS E1 RC AT 7
CONNECT IS E1 RC AT 11
CONNECT IS E1 RC AT 12
CONNECT IS E1 RC AT 14
CONNECT IS E1 RC AT 16
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 23
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L48 STR



VAR G1=X/7/8/10/13/15/22/19/22/17/CN/NO2/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 1
NSPEC IS RC AT 2
CONNECT IS E2 RC AT 3
CONNECT IS E1 RC AT 7
CONNECT IS E1 RC AT 11
CONNECT IS E1 RC AT 12
CONNECT IS E1 RC AT 14
CONNECT IS E1 RC AT 16
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 23
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L50 273 SEA FILE=REGISTRY SUB=L15 SSS FUL (L17 AND (L20 OR L46 OR L47 OR L48))

=> b hcaplus
FILE 'HCAPLUS' ENTERED AT 11:28:09 ON 11 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Feb 2004 VOL 140 ISS 7
FILE LAST UPDATED: 10 Feb 2004 (20040210/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que l51 nos
L6 STR
L7 STR
L8 STR
L9 (6520) SEA FILE=REGISTRY SSS FUL L6
L10 (747) SEA FILE=REGISTRY SUB=L9 SSS FUL (L6 AND (L7 OR L8))
L11 STR
L12 STR
L13 STR
L14 STR
L15 544 SEA FILE=REGISTRY SUB=L10 SSS FUL (L6 AND L14 NOT (L11 OR L12 OR L13))
L17 STR
L20 STR
L46 STR
L47 STR
L48 STR
L50 273 SEA FILE=REGISTRY SUB=L15 SSS FUL (L17 AND (L20 OR L46 OR L47 OR L48))
L51 44 SEA FILE=HCAPLUS ABB=ON PLU=ON L50

=> d ibib abs hitstr 151 1-44

151 ANSWER 1 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:20494 HCAPLUS
DOCUMENT NUMBER: 140:77140
TITLE: Preparation of thiazolyl aryl ureas as activators of glucokinase
INVENTOR(S): Polisetti, Dharma Rao; Kodra, Janos Tibor; Lau, Jesper; Bloch, Paw; Valcarce-Lopez, Maria Carmen; Blume, Niels; Guzel, Mustafa; Santhosh, Kalpathy Chidambareswaran; Mjalli, Adnan M. M.; Andrews, Robert Carl; Subramanian, Govindan; Ankersen, Michael; Vedso, Per; Murray, Anthony; Jeppesen, Lone
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Valcarce-Lopez,mariacarmen; et al.
SOURCE: PCT Int. Appl., 600 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002481	A1	20040108	WO 2003-DK449	20030627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
DK 2002-999 A 20020627
US 2002-394144P P 20020703
DK 2003-286 A 20030225
US 2003-452228P P 20030305

GI



I



II

AB The title compds. [I; A1 = arylene, heteroarylene, fused cycloalkylarylene, etc.; L1 = a bond, O, S, SO, etc.; G1 = alkyl, cycloalkyl, cycloalkylalkylene, etc.; L2 = a bond, alkylene, alkenylene,

etc.; L3 = CO, COCO, COCH2CO, SO2; R1 = alkyl, alkenyl, alkynyl, etc.; G2 = heteroaryl, fused heterocyclylheteroaryl, cycloalkylheteroaryl, etc.] which are activators of glucokinase and may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial (no data), were prepared and formulated. Thus, reacting 2-phenoxyaniline with 2-aminothiazole and 1,1'-carbonyldiimidazole afforded 95% the urea II.

IT **361394-40-3**, 2-Fluoro-6-(4-methoxyphenoxy)benzylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolyl aryl ureas as glucokinase activators)

RN 361394-40-3 HCAPLUS

CN Benzenemethanamine, 2-fluoro-6-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 2 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:777769 HCAPLUS
DOCUMENT NUMBER: 139:261302
TITLE: Preparation of aminobenzamide derivatives for treatment of diabetes and obesity
INVENTOR(S): Nishimura, Teruyuki; Iino, Tomoharu; Nagata, Yasufumi; Eiki, Junichi
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080585	A1	20031002	WO 2003-JP3656	20030325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-85720 A 20020326
OTHER SOURCE(S): MARPAT 139:261302

GI



I

AB Title compds. I (R = nitrogen-containing, monocyclic or bicyclic heteroaryl group; R1 = heterocyclylthio, heterocyclylsulfinyl, heterocyclylsulfonyl, etc.; R2 = H, halo, alkyl, etc.; X1, X2 = N, CH) and their pharmaceutically acceptable salts, having glucokinase activity and useful for prevention or treatment of diabetes and obesity, are prepared 2-Amino-5-(4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(4-methylthiazol-2-yl)benzamide was prepared and showed hypoglycemic activity in mice.

IT **603109-35-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzamide derivs. for treatment of diabetes and obesity)

RN 603109-35-9 HCAPLUS

CN Benzamide, 2-amino-5-[2-[(dimethylamino)methyl]phenoxy]-N-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 3 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:696859 HCAPLUS
DOCUMENT NUMBER: 139:230480
TITLE: Preparation of substituted amines prodrugs useful in treating Alzheimer's disease
INVENTOR(S): Varghese, John; Jagodzinska, Barbara; Maillard, Michel; Beck, James P.; Tenbrink, Ruth E.; Getman, Daniel
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
SOURCE: PCT Int. Appl., 483 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072535	A2	20030904	WO 2003-US7287	20030227

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-359953P P 20020227

OTHER SOURCE(S): MARPAT 139:230480

GI



I



II

AB Amines [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO2, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.; e.g. N1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N3,N3-dipropylisophthalamide], useful in treating Alzheimer's disease and other similar diseases, were prepared Although the methods of preparation are not claimed, hundreds of example prepns. are included. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamic acid in the presence of Et3N,

1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II (N1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N3,N3-dipropylisophthalamide). The compds. I exhibit an IC50 of < 50 μM against β-secretase.

IT **175136-89-7**, [(2-Chloro-6-phenoxyphenyl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted amine prodrugs useful in treating Alzheimer's disease)

RN 175136-89-7 HCAPLUS
CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 4 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:678291 HCAPLUS
DOCUMENT NUMBER: 139:202503
TITLE: Osmotic delivery system containing a polyethylene oxide and an osmagent
INVENTOR(S): Waterman, Kenneth C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003161882	A1	20030828	US 2003-352258	20030127

PRIORITY APPLN. INFO.: US 2002-353502P P 20020201

AB An osmotic pharmaceutical tablet is described which comprises a single-layer compressed core surrounded by a water permeable layer having a passageway. The single-layer core contains (i) a non-ripening drug having a solubility per dose less than about 1 mL -1 , (ii) about 2.0% to about 30% by weight of a polyethylene oxide having a weight-average, mol. weight from about 200,000 to about 7,000,000, (iii) an osmagent, and (iv) an optional disintegrant. Many osmotic tablets were prepared and their dissoln. rate were studied.

IT **289716-93-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osmotic delivery system containing polyethylene oxide and osmagent)

RN 289716-93-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 5 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:416216 HCAPLUS
DOCUMENT NUMBER: 139:337765
TITLE: Microwave-assisted synthesis of phthalonitriles and phthalocyanines
AUTHOR(S): Csokai, Viktor; Parlagh, Gyula; Grofcsik, Andras; Kubinyi, Miklos; Bitter, Istvan
CORPORATE SOURCE: Department of Organic Chemical Technology, Budapest University of Technology and Economics, Budapest, H-1521, Hung.
SOURCE: Synthetic Communications (2003), 33(10), 1615-1621
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The microwave-assisted synthesis of phthalonitriles such as I [R = Me(OCH2CH2)2] and phthalocyanines such as II (same R; M = Zn, 2H) using a two-step literature method was compared with that of a one pot procedure. The two step literature method, comprising first the preparation of the appropriate phthalonitrile followed by cyclization, generally used for the synthesis of Pcs was affected by microwave (Mw) irradiation The synthetic route was based on the well known nucleophilic substitution of 4-nitrophthalonitrile with alcs. and phenols in the presence of K2CO3 in DMF solvent. The one pot procedure provides remarkable advantages compared with the two step synthesis of Pc-Zn complexes: the overall yields are comparable, the expensive DBU can be eliminated, the work-up is easier, and this method is suitable for direct preparation of metal-free Pcs.

IT **615249-96-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(microwave-assisted synthesis of phthalonitriles and phthalocyanines)

RN 615249-96-2 HCAPLUS

CN 1,2-Benzenedicarbonitrile, 4-[2,4-bis[(dimethylamino)methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 6 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:289083 HCAPLUS

DOCUMENT NUMBER: 139:360973

TITLE: Molecular modeling of potential new and selective PET radiotracers for the serotonin transporter

AUTHOR(S): Wellsow, Julia; Kovar, Karl-Artur; Machulla, Hans-Jurgen

CORPORATE SOURCE: Pharmaceutical Institute, Department of Pharmaceutical and Analytical Chemistry, University of Tubingen, Tubingen, Germany

SOURCE: Journal of Pharmacy & Pharmaceutical Sciences [online computer file] (2002), 5(3), 245-257
CODEN: JPPSFY; ISSN: 1482-1826
URL: http://www.ualberta.ca/~csps/JPPS5(3)/K.Kovar/pet.pdf

PUBLISHER: Canadian Society for Pharmaceutical Sciences

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB Imaging the serotonin transporter (SERT) with Positron Emission Tomog. (PET) provides a useful tool for understanding alterations of the serotonergic system. However, no optimal PET radiotracer for the SERT yet exists. The main purpose of this study was to design potential new and

selective PET radiotracers for the SERT and to predict their binding affinity at both the SERT and the norepinephrine transporter. Mol. Modeling was used for ligand design. Predictions of binding affinity were based on models generated by Comparative Mol. Field Anal. (CoMFA) and Comparative Mol. Similarity Indexes Anal. (CoMSIA). A series of 100 compds. were suggested. As di-Ph sulfide derivs. like [11C]DASB have recently proven to be promising PET ligands, rational modification of the di-Ph sulfide scaffold has been performed. The novel compds. were predicted to be selective high affinity SERT ligands. Important new ideas are the introduction of a fluoroethyl-oxycarbonyl group (ester) and fluoroethyl-carbonyl group (ketone), as well as a formyl group (aldehyde), and its corresponding oxime and imine. Another innovative suggestion is the replacement of the sulfur bridge with a cyanamide group and a fluoroethylamino group. The suggested compds. possess features providing new possibilities for carbon-11 or fluorine-18 labeling. Synthesis, biol. testing, and screening for PET suitability are reasonably further steps.

IT **622399-66-0 622399-67-1 622399-68-2 622399-69-3**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(mol. modeling of PET radiotracers for serotonin transporter)

RN 622399-66-0 HCAPLUS
CN Benzonitrile, 3-amino-4-[2-[(dimethylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 622399-67-1 HCAPLUS
CN Benzenemethanamine, 2-[2-amino-4-(2-fluoroethyl)phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 622399-68-2 HCAPLUS
CN Benzoic acid, 3-amino-4-[2-[(dimethylamino)methyl]phenoxy]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)



RN 622399-69-3 HCAPLUS
CN 1-Propanone, 1-[3-amino-4-[2-[(dimethylamino)methyl]phenoxy]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 7 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:925264 HCAPLUS
DOCUMENT NUMBER: 138:11431
TITLE: 5-HT1a antagonist or an α2-adrenergic antagonist in combination with an serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1262197	A2	20021204	EP 2002-253589	20020522
EP 1262197	A3	20021218		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2002183306 A1 20021205 US 2002-75849 20020213
BR 2002001974 A 20030422 BR 2002-1974 20020528
JP 2003026602 A2 20030129 JP 2002-155222 20020529
PRIORITY APPLN. INFO.: US 2001-294322P P 20010530
OTHER SOURCE(S): MARPAT 138:11431

AB The invention provides a method of treating sleep disorders, including sleep apnea, in a mammal, including a human, by administering to the mammal a 5-HT1a antagonist or an α2-adrenergic antagonist in combination with an serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in efficacy. Also provided are pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5-HT1a antagonist or an α2-adrenergic antagonist, and an SRI antidepressant agent.

IT **289716-79-6 289716-94-5 289717-01-7**
289717-16-4 289717-18-6 289717-48-2
289717-50-6 289717-52-8 289717-56-2
289717-57-3 289717-59-5 289717-60-8
289717-61-9 289717-62-0 289717-63-1
289717-64-2 289717-65-3 289717-66-4
289717-67-5 289717-68-6 289717-69-7
289717-70-0 289717-71-1 289717-72-2
289717-73-3 289717-74-4 289717-75-5
444888-21-5 444888-22-6 444888-23-7
444888-24-8 444888-25-9 444888-27-1
444888-29-3 444888-31-7 444888-33-9
444888-34-0 444888-35-1 444888-36-2
444888-37-3 444888-38-4 444888-39-5
444888-40-8 444888-41-9 444888-42-0
444888-43-1 444888-45-3 444888-46-4
444888-49-7 454456-66-7 477337-55-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT1a antagonist or α2-adrenergic antagonist in combination with serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea)

RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-21-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α,α-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-22-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N,α,α-tetramethyl- (9CI) (CA INDEX NAME)



RN 444888-23-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-24-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-25-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-27-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 444888-29-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-31-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-33-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α,α-trimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-34-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-35-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-36-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfinyl)-(9CI) (CA INDEX NAME)



RN 444888-37-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-(9CI) (CA INDEX NAME)



Searched by P. Ruppel

RN 444888-38-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 444888-39-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 444888-40-8 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 444888-41-9 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-42-0 HCAPLUS
CN Morpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-43-1 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-45-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-46-4 HCAPLUS
CN Thiomorpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-49-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 454456-66-7 HCAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 477337-55-6 HCAPLUS
CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N-methyl- (9CI) (CA INDEX NAME)



L51 ANSWER 8 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:925263 HCAPLUS
DOCUMENT NUMBER: 138:336
TITLE: Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1262196	A2	20021204	EP 2002-253105	20020502
EP 1262196	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002370975	A2	20021224	JP 2002-132804	20020508
AU 2002040686	A5	20021205	AU 2002-40686	20020516

US 2003130322 A1 20030710 US 2002-153379 20020522
CN 1386503 A 20021225 CN 2002-120350 20020523
PRIORITY APPLN. INFO.: US 2001-293088P P 20010523
OTHER SOURCE(S): MARPAT 138:336
GI



I

AB The present invention relates to a method of treating alcoholism or alc. dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist. An example monoamine reuptake inhibitor is I.

IT **289716-79-6 289716-94-5 289717-01-7**
289717-16-4 289717-18-6 289717-24-4
289717-48-2 289717-50-6 289717-52-8
289717-53-9 289717-54-0 289717-55-1
289717-56-2 289717-57-3 289717-58-4
289717-59-5 289717-60-8 289717-61-9
289717-62-0 289717-63-1 289717-64-2
289717-65-3 289717-66-4 289717-67-5
289717-68-6 289717-69-7 289717-70-0
289717-71-1 289717-72-2 289717-73-3
289717-74-4 289717-75-5 364323-82-0
476310-75-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alc. dependence)

RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

Searched by P. Ruppel



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 364323-82-0 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 476310-75-5 HCAPLUS
CN Benzenemethanamine, 5-fluoro-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Searched by P. Ruppel



L51 ANSWER 9 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:904325 HCAPLUS
DOCUMENT NUMBER: 137:380038
TITLE: Combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1260221	A2	20021127	EP 2002-253135	20020503
EP 1260221	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2002040681	A5	20021205	AU 2002-40681	20020516
JP 2002370976	A2	20021224	JP 2002-141515	20020516
CN 1386504	A	20021225	CN 2002-120351	20020523

PRIORITY APPLN. INFO.: US 2001-293063P P 20010523
OTHER SOURCE(S): MARPAT 137:380038

AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.

IT **289716-79-6 289716-94-5 289717-01-7**
289717-16-4 289717-18-6 289717-24-4
289717-48-2 289717-50-6 289717-52-8
289717-53-9 289717-54-0 289717-55-1
289717-56-2 289717-57-3 289717-58-4
289717-59-5 289717-60-8 289717-61-9
289717-62-0 289717-63-1 289717-64-2
289717-65-3 289717-66-4 289717-67-5
289717-68-6 289717-69-7 289717-70-0
289717-71-1 289717-72-2 289717-73-3
289717-74-4 289717-75-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoamine reuptake inhibitor; combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety)

RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



L51 ANSWER 10 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:773622 HCAPLUS
DOCUMENT NUMBER: 137:273225
TITLE: Combination treatment for multiple sclerosis, other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1247533	A2	20021009	EP 2002-251844	20020314
EP 1247533	A3	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002147206	A1	20021010	US 2001-24968	20011219
JP 2002356445	A2	20021213	JP 2002-100682	20020403
BR 2002001094	A	20030527	BR 2002-1094	20020405

PRIORITY APPLN. INFO.: US 2001-281988P P 20010405
OTHER SOURCE(S): MARPAT 137:273225

AB The invention relates to a combination useful in treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal comprising a neurotransmitter-inducing or precursor agent in combination with an (serotonin reuptake inhibitors, SRI) anxiolytic agent or an antidepressant with improvement in efficiency. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a neurotransmitter-inducing or precursor agent, and an SRI antidepressant or anxiolytic agent.

IT **107624-14-6 107624-14-6D**, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination treatment for multiple sclerosis, demyelinating conditions and peripheral neuropathy)

RN 107624-14-6 HCAPLUS

CN Benzenemethanamine, 2-phenoxy- (9CI) (CA INDEX NAME)



RN 107624-14-6 HCAPLUS
CN Benzenemethanamine, 2-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 11 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:755211 HCAPLUS
DOCUMENT NUMBER: 137:262839
TITLE: Preparation of phenoxybenzylamines as monoamine reuptake inhibitors for treatment of CNS disorders.
INVENTOR(S): Howard, Harry R.; Schmidt, Christopher J.; Seeger, Thomas F.; Elliott, Mark L.
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 529,207.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143003	A1	20021003	US 2001-845992	20010430
US 6677378	B2	20040113		
WO 2000050380	A1	20000831	WO 2000-IB108	20000202

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-121313P P 19990223
US 2000-529207 A2 20000202
WO 2000-IB108 W 20000202
OTHER SOURCE(S): MARPAT 137:262839
AB ROZCR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl;

NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prepared as monoamine reuptake inhibitors (no data). Such compds. are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

IT **289718-11-2P**, Benzenemethanamine, 2-(4-methylphenoxy)-
RL: BYP (Byproduct); PREP (Preparation)
(preparation of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 289718-11-2 HCAPLUS

CN Benzenemethanamine, 2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



IT **146520-69-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-, hydrochloride **146797-20-8P**, Benzenemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) **289716-74-1P**, Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- **289716-75-2P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- **289716-79-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- **289716-80-9P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) **289716-82-1P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-, hydrochloride **289716-85-4P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (4:3) **289716-88-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-ethyl-, (2Z)-2-butenedioate (1:1) **289716-89-8P**, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride **289716-91-2P**, Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) **289716-92-3P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-, hydrochloride **289716-93-4P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride **289716-94-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- **289716-95-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) **289716-96-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- **289716-97-8P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride **289716-98-9P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl-, hydrochloride **289717-00-6P**, Benzenemethanamine, N,N-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) **289717-01-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- **289717-02-8P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) **289717-04-0P**, Benzenemethanamine, 2-(3,4-difluorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) **289717-06-2P**, Benzenemethanamine,

2-(3,4-difluorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-08-4P**, Benzenemethanamine, N,α-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) **289717-09-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride **289717-11-9P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) **289717-13-1P**, Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-15-3P**, Benzenemethanamine, 2-(3,4-dimethylphenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-16-4P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- **289717-17-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) **289717-18-6P**, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- **289717-19-7P**, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-23-3P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-24-4P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- **289717-25-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (2Z)-2-butenedioate (1:1) **289717-26-6P**, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl-, hydrochloride **289717-28-8P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) **289717-29-9P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-, hydrochloride **289717-30-2P**, Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl-, hydrochloride **289717-32-4P**, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) **289717-33-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl-, hydrochloride **289717-34-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-, hydrochloride **289717-35-7P**, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride **289717-36-8P**, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride **289717-37-9P**, Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride **289717-38-0P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride **289717-39-1P**, Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-, monohydrochloride **289717-41-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-, hydrochloride **289717-42-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride **289717-43-7P**, Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)- **289717-44-8P**, Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) **289717-45-9P**, Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-, monohydrochloride **289717-46-0P**, Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl- **289717-47-1P**, Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-, monohydrochloride **289717-48-2P**, Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- **289717-49-3P**, Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, hydrochloride **289717-50-6P**, Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- **289717-51-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-, hydrochloride **289717-52-8P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-

289717-53-9P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- **289717-54-0P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- **289717-55-1P**, Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- **289717-56-2P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- **289717-57-3P**, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- **289717-58-4P**, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- **289717-59-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- **289717-60-8P**, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- **289717-61-9P**, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- **289717-62-0P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- **289717-63-1P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- **289717-64-2P**, Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- **289717-65-3P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- **289717-66-4P**, Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- **289717-67-5P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- **289717-68-6P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- **289717-69-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- **289717-70-0P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- **289717-71-1P**, Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- **289717-72-2P**, Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- **289717-73-3P**, Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- **289717-74-4P**, Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- **289717-75-5P**, Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- **289719-21-7P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride **289719-22-8P**, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 146520-69-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 146797-20-8 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146797-19-5
CMF C15 H16 Cl N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-74-1 HCAPLUS
CN Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289716-75-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- (9CI) (CA INDEX NAME)



RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-80-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-79-6
CMF C16 H14 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

Searched by P. Ruppel



RN 289716-82-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 289716-85-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (4:3) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-84-3
CMF C14 H13 Cl2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-88-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-ethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-87-6
CMF C15 H15 Cl2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-89-8 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-91-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-90-1
CMF C14 H14 Cl N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-92-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Searched by P. Ruppel



● HCl

RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289716-95-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-94-5
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Searched by P. Ruppel

Double bond geometry as shown.



RN 289716-96-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- (9CI) (CA INDEX NAME)



RN 289716-97-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-98-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-00-6 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-99-0
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-02-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-01-7
CMF C16 H14 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-04-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-difluorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-03-9
CMF C15 H15 F2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-06-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-difluorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-05-1
CMF C14 H13 F2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-08-4 HCAPLUS
CN Benzenemethanamine, N,α-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-07-3
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-09-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 289717-11-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-10-8
CMF C15 H12 Cl2 F3 N O





CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-13-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-12-0
CMF C16 H18 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-15-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-14-2
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 289717-17-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-16-4
CMF C15 H12 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-19-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-18-6
CMF C14 H12 Cl3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-23-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-25-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-24-4
CMF C15 H14 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-26-6 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-28-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-27-7
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-29-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-30-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-32-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-31-3
CMF C15 H15 Cl F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-33-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-34-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-35-7 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-36-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-37-9 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 289717-38-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-39-1 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-41-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-42-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-43-7 HCAPLUS
CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289717-44-8 HCAPLUS
CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-43-7
CMF C16 H18 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-45-9 HCAPLUS
CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-46-0 HCAPLUS
CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-47-1 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-49-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, hydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-51-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)-

(9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 289719-21-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289719-22-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



L51 ANSWER 12 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:674788 HCAPLUS
DOCUMENT NUMBER: 137:195595
TITLE: Atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis
INVENTOR(S): Howard, Harry R., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002123490	A1	20020905	US 2001-10651	20011206
EP 1238676	A1	20020911	EP 2002-251153	20020220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002308801	A2	20021023	JP 2002-50579	20020227

PRIORITY APPLN. INFO.: US 2001-272619P P 20010301
OTHER SOURCE(S): MARPAT 137:195595

AB The invention provides a method for treating depression, obsessive compulsive disorder, and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also provides pharmaceutical compns. containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and a serotonin reuptake inhibitor.

IT **289716-79-6 289716-94-5 289717-01-7**
289717-16-4 289717-18-6 289717-24-4
289717-48-2 289717-50-6 289717-52-8
289717-53-9 289717-54-0 289717-55-1
289717-56-2 289717-57-3 289717-58-4
289717-59-5 289717-60-8 289717-61-9
289717-62-0 289717-63-1 289717-64-2
289717-65-3 289717-66-4 289717-67-5
289717-68-6 289717-69-7 289717-70-0
289717-71-1 289717-72-2 289717-73-3
289717-74-4 289717-75-5 444888-21-5

444888-23-7 444888-24-8 444888-25-9
444888-27-1 444888-28-2 444888-29-3
444888-30-6 444888-31-7 444888-32-8
444888-33-9 444888-34-0 444888-35-1
444888-36-2 444888-37-3 444888-38-4
444888-39-5 444888-40-8 444888-41-9
444888-42-0 444888-43-1 444888-45-3
444888-46-4 444888-49-7 454456-38-3
454456-43-0 454456-66-7 454456-75-8
454473-98-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)

RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-21-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α,α-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-23-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-24-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-25-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-27-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 444888-28-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 444888-29-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-30-6 HCAPLUS
CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-α-ethyl-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-31-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-32-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-33-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α,α-trimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-34-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-35-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-36-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfinyl)-(9CI) (CA INDEX NAME)



RN 444888-37-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-(9CI) (CA INDEX NAME)



RN 444888-38-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 444888-39-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 444888-40-8 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 444888-41-9 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-42-0 HCAPLUS
CN Morpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-43-1 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-45-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-46-4 HCAPLUS
CN Thiomorpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-49-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 454456-38-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 454456-43-0 HCAPLUS
CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 454456-66-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 454456-75-8 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 454473-98-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-ar-fluoro-N-methyl- (9CI) (CA INDEX NAME)



D1—F

L51 ANSWER 13 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:595509 HCAPLUS
DOCUMENT NUMBER: 137:135106
TITLE: Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression
INVENTOR(S): Howard, Harry R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002107244	A1	20020808	US 2001-2303	20011102
EP 1230921	A1	20020814	EP 2002-250541	20020128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002275097	A2	20020925	JP 2002-20186	20020129
BR 2002000246	A	20021029	BR 2002-246	20020131

PRIORITY APPLN. INFO.: US 2001-266340P P 20010202
OTHER SOURCE(S): MARPAT 137:135106

AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and especially between 0.01 to I and 100 to 1 (no data).

IT **289716-79-6 289716-94-5 289717-01-7**
289717-16-4 289717-18-6 289717-24-4
289717-48-2 289717-50-6 289717-52-8
289717-53-9 289717-54-0 289717-55-1
289717-56-2 289717-57-3 289717-58-4
289717-59-5 289717-60-8 289717-61-9
289717-62-0 289717-63-1 289717-64-2
289717-65-3 289717-66-4 289717-67-5

289717-68-6 289717-69-7 289717-70-0
289717-71-1 289717-72-2 289717-73-3
289717-74-4 289717-75-5 444888-21-5
444888-22-6 444888-23-7 444888-24-8
444888-25-9 444888-26-0 444888-27-1
444888-28-2 444888-29-3 444888-30-6
444888-31-7 444888-32-8 444888-33-9
444888-34-0 444888-35-1 444888-36-2
444888-37-3 444888-38-4 444888-39-5
444888-40-8 444888-41-9 444888-42-0
444888-43-1 444888-45-3 444888-46-4
444888-48-6 444888-49-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)

RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-21-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α,α-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-22-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N,α,α-tetramethyl- (9CI) (CA INDEX NAME)



RN 444888-23-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-24-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-25-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-26-0 HCAPLUS
CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-27-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 444888-28-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 444888-29-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-30-6 HCAPLUS
CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-α-ethyl-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-31-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-32-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-33-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α,α-trimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-34-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 444888-35-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-36-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-37-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 444888-38-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 444888-39-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 444888-40-8 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 444888-41-9 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 444888-42-0 HCAPLUS
CN Morpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-43-1 HCAPLUS
CN Piperidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-45-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 444888-46-4 HCAPLUS
CN Thiomorpholine, 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 444888-48-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-(propylsulfonyl)- (9CI) (CA INDEX NAME)



RN 444888-49-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





L51 ANSWER 14 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:293652 HCAPLUS
DOCUMENT NUMBER: 136:325531
TITLE: Preparation of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors
INVENTOR(S): Anthony, Neville J.; Gomez, Robert P.; Young, Steven D.; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Embrey, Mark; Tran, Lekhanh; Melamed, Jeffrey Y.; Langford, H. Marie; Guare, James P.; Fisher, Thorsten E.; Jolly, Samson M.; Kuo, Michelle S.; Perlow, Debra S.; Bennett, Jennifer J.; Funk, Timothy W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 434 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030930	A2	20020418	WO 2001-US31456	20011009
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011527	A5	20020422	AU 2002-11527	20011009
EP 1326865	A2	20030716	EP 2001-979582	20011009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003055071	A1	20030320	US 2001-973853	20011010
PRIORITY APPLN. INFO.:			US 2000-239707P P	20001012
			US 2001-281656P P	20010405
			WO 2001-US31456 W	20011009

OTHER SOURCE(S): MARPAT 136:325531

GI



I



II

AB Title compds., including certain quinoline carboxamide and naphthyridine carboxamide derivs., I [wherein A = (un)substituted Ph or Ph fused to a carbocycle; L = a single bond, or (un)substituted alkyl, alkenyl, alkylcycloalkylalkyl, or alkyl-M-alkyl; M = NRa, OCO, or CO2; X = N or CQ1; Y = N or CQ2, provided that X and Y are not both N; Z1 = N or CQ3; Z2 = N or CQ4; Z3 = N or CH; Q1-Q4 = independently H, halo, CN, NR1CR1O, or (un)substituted alkyl, alkoxy, alkenyl, alkynyl, carbamoyl, carboximidamido, amino, etc.; or C2Q2Q3 = (un)substituted 5- or 6-membered carbocycle or heterocycle; R1 and R2 = independently H, OH, halo, NO2, CN, or (un)substituted alkyl, alkenyl, alkoxy, amino, sulfonylamino, etc.; R3 and R4 = independently H, halo, CN, NO2, OH, alkenyl, or (un)substituted alkyl, amino, sulfonylamino, etc.; R5 = H, CN, CN, or (un)substituted

alkyl or aryl; Ra = independently H or (halo)alkyl; or pharmaceutically acceptable salts thereof] were prepared I are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compds. or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics, or vaccines. For example, Mitsunobu reaction of iso-Pr 3-(hydroxymethyl)pyridine-2-carboxylate with Me N-[(4-methylphenyl)sulfonyl]glycinate, followed by cyclization in the presence on NaOMe, afforded Me 8-hydroxy-1,6-naphthyridine-7-carboxylate. Coupling with 3,5-dichlorobenzylamine in toluene gave II. Representative compds. were assayed for the inhibition of acute HIV infection of T-lymphoid cells and demonstrated IC95 values of < 20 μM.

IT **175136-89-7**, 2-Aminomethyl 3-chlorodiphenyl ether
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors for treatment of AIDS)

RN 175136-89-7 HCAPLUS

CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 15 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:171851 HCAPLUS

DOCUMENT NUMBER: 136:232110

TITLE: Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors

INVENTOR(S): Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018333	A1	20020307	WO 2001-IB1521	20010822

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001078650	A5	20020313	AU 2001-78650	20010822
EP 1313701	A1	20030528	EP 2001-956734	20010822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013610	A	20030624	BR 2001-13610	20010822
US 2003060456	A1	20030327	US 2001-941177	20010827
US 6610747	B2	20030826		
BG 107544	A	20031031	BG 2003-107544	20030207
NO 2003000842	A	20030428	NO 2003-842	20030224
HR 2003000141	A1	20030430	HR 2003-141	20030226

PRIORITY APPLN. INFO.:

GB 2000-21593	A	20000831
GB 2001-7116	A	20010321
US 2000-240271P	P	20001013
US 2001-292400P	P	20010521
WO 2001-IB1521	W	20010822

OTHER SOURCE(S): MARPAT 136:232110

GI



I



II

AB Title compds. I [R1 and R2 independently = H, alkyl or (CH2)n(C3-C6cycloalkyl) wherein n = 0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached from an azetidine ring; Z or Y is -SR3 and the other Z or Y is halogen or -R3; wherein R3 = C1-4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from O, S and N; R4 and R5 independently = A-X, wherein A = -CH=CH- or -(CH2)p- where p is 0, 1 or 2; X = H, halo, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, etc; or A-X = (un)substituted 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O; R6 and R7 independently = H, (un)substituted alkyl; or R6 and R7 together with the N to which they are attached form a (un)substituted 4-6 membered heterocyclic ring] and there pharmaceutically acceptable salts are prepared

Thus, II was prepared via substitution of 5-(aminosulfonyl)-2-fluoro-N-methylbenzamide by 2,3-dihydrobenzo[b]thiophen-5-ol with successive BF3·THF catalyzed amide reduction, formylation of secondary amine, and reduction II demonstrated a serotonin re-uptake inhibition IC50 of 4.7nM. I inhibit monoamine re-uptake and in particular exhibit activity as selective serotonin reuptake inhibitors.

IT **402912-23-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402912-23-6 HCAPLUS
CN Benzenemethanamine, N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-5-nitro- (9CI) (CA INDEX NAME)



IT **402910-43-4P 402910-50-3P 402910-61-6P**
402910-62-7P 402910-90-1P 402910-96-7P
402911-10-8P 402911-12-0P 402911-20-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402910-43-4 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-5-nitro- (9CI) (CA INDEX NAME)



RN 402910-50-3 HCAPLUS
CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 402910-61-6 HCAPLUS
CN Benzenemethanamine, 5-bromo-N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)



RN 402910-62-7 HCAPLUS
CN Benzenemethanamine, N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-90-1 HCAPLUS
CN Benzonitrile, 4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-96-7 HCAPLUS
CN Benzonitrile, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-10-8 HCAPLUS
CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-12-0 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-,

hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-20-0 HCAPLUS
CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



IT **402910-41-2P 402910-54-7P 402910-56-9P 402910-59-2P 402910-60-5P 402911-11-9P 402911-49-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402910-41-2 HCAPLUS
CN Benzenemethanamine, 5-methoxy-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-54-7 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-56-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-[3-chloro-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 402910-59-2 HCAPLUS
CN Benzenemethanamine, 2-[(2,3-dihydro-1H-inden-5-yl)oxy]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)



RN 402910-60-5 HCAPLUS
CN Benzenemethanamine, 5-methoxy-N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-11-9 HCAPLUS
CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-49-3 HCAPLUS
CN Benzonitrile, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 16 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:169117 HCAPLUS
DOCUMENT NUMBER: 136:216641

TITLE: Preparation of phenoxyphenylheterocycles as selective serotonin reuptake inhibitors (SSRIs)
INVENTOR(S): Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1184372	A1	20020306	EP 2001-307032	20010817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002183303	A1	20021205	US 2001-939475	20010824
US 6630504	B2	20031007		
BR 2001003797	A	20020604	BR 2001-3797	20010830

PRIORITY APPLN. INFO.: GB 2000-21594 A 20000831
GB 2001-5634 A 20010307
US 2000-240326P P 20001013

OTHER SOURCE(S): MARPAT 136:216641
GI



I



II

AB The title compds. [I; R1 = H, alkyl; R2, R3, together with the interconnecting atoms, form a 4-8 membered saturated ring containing 1-2 heteroatoms (including the N atom to which R2 is attached) wherein a second heteroatom, if present, is selected from O, N and S; Z = CF3, OCF3, alkylthio or alkoxy; Y = H, halo, ORa, Ra or alkylthio (wherein Ra = alkyl optionally substituted with F atoms); or when Z and Y are attached para and meta to the ether linkage linking rings A and B, Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5-7 membered carbocyclic or heterocyclic ring which may be saturated, unsatd. or aromatic; R4, R5 = AX (wherein A = CH:CH, (CH2)p; p = 0-2; X = H, F, Cl, OH, etc.)] and their salts, useful for the treatment of prevention of a disorder in which the regulation of monoamine transporter function is implicated, were prepared and formulated. Thus, reducing

5-{2-[4-(methylsulfanyl)phenoxy]phenyl}-3,4-dihydro-2H-pyrrole (preparation given) with NaBH4 in EtOH afforded 72% II.HCl which showed IC50 of ≤ 100 nM in test for serotonin re-uptake inhibition.

IT **402714-37-8P 402714-38-9P 402714-39-0P**
402714-48-1P 402714-52-7P 402714-53-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phenoxyphenylpyrrolidines as selective serotonin reuptake inhibitors (SSRIs))

RN 402714-37-8 HCAPLUS
CN Pyrrolidine, 2-[2-[4-(methylthio)phenoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402714-38-9 HCAPLUS
CN Pyrrolidine, 2-[2-[4-(trifluoromethyl)phenoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402714-39-0 HCAPLUS
CN Pyrrolidine, 2-[2-[4-(trifluoromethoxy)phenoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402714-48-1 HCAPLUS
CN Pyrrolidine, 1-methyl-2-[2-[4-(methylthio)phenoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402714-52-7 HCAPLUS
CN Pyrrolidine, 2-[5-nitro-2-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 402714-53-8 HCAPLUS
CN Pyrrolidine, 2-[5-nitro-2-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



IT **402714-40-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyphenylpyrrolidines as selective serotonin reuptake inhibitors (SSRIs))
RN 402714-40-3 HCAPLUS
CN Pyrrolidine, 2-[5-bromo-2-[(2,3-dihydro-1H-inden-5-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



IT **402714-74-3P 402714-75-4P 402714-94-7P**
402714-95-8P 402714-96-9P 402714-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenoxyphenylpyrrolidines as selective serotonin reuptake inhibitors (SSRIs))
RN 402714-74-3 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[5-amino-2-[4-(trifluoromethoxy)phenoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402714-75-4 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[5-amino-2-[4-(trifluoromethyl)phenoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402714-94-7 HCAPLUS
CN Pyrrolidine, 2-[2-[4-(methylthio)phenoxy]phenyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 402714-95-8 HCAPLUS
CN Pyrrolidine, 1-(trifluoroacetyl)-2-[2-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 402714-96-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[5-nitro-2-[4-(trifluoromethoxy)phenoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402714-97-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[5-nitro-2-[4-(trifluoromethyl)phenoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 17 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:730683 HCAPLUS
DOCUMENT NUMBER: 135:288572
TITLE: Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
INVENTOR(S): Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072687	A1	20011004	WO 2001-IB428	20010319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002052395	A1	20020502	US 2001-810378	20010316
US 6448293	B2	20020910		
EP 1268396	A1	20030102	EP 2001-917347	20010319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009547	A	20030610	BR 2001-9547	20010319
NZ 519972	A	20030725	NZ 2001-519972	20010319
JP 2003528845	T2	20030930	JP 2001-570602	20010319
BG 106912	A	20030131	BG 2002-106912	20020709
NO 2002004663	A	20020927	NO 2002-4663	20020927

PRIORITY APPLN. INFO.:	GB 2000-7884	A	20000331
	US 2000-197127P	P	20000414
	WO 2001-IB428	W	20010319

OTHER SOURCE(S): MARPAT 135:288572

GI



I



II

AB Title compds. I [wherein R1 and R2 = independently H or (cycloalkyl)alkyl; or R1 and R2 together with the N to which they are attached form an azetidine ring; R3 = independently CF3, OCF3, alkylthio, or alkoxy; n = 1-3; R4 and R5 = independently AX; A = CH:CH or (CH2)p; p = 0-2; X = H, halo, OH, alkoxy, NO2, CN, CHO, alkylthio, alkylsulfinyl, alkylsulfonyl, or (un)substituted carbamoyl, sulfamoyl, amino, carboxy, etc.; or pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prepared as monoamine re-uptake inhibitors, particularly as selective serotonin re-uptake inhibitors. For example, 4-(methylmercapto)phenol was

coupled with 2-fluorobenzaldehyde using K2CO3 in DMF to give 2-[4-(methylsulfanyl)phenoxy]benzaldehyde (100%). The aldehyde was dissolved in THF, DCM, Me2NH•HCl, and TEA, treated with NaBH(OAc)3, and converted to the salt with 1M HCl in Et2O to afford N,N-dimethyl-N-[2-[4-(methylsulfanyl)phenoxy]benzyl]amine•HCl (84%). Coupling the salt with ClSO3H in CH2Cl2 at 0° to 5°C, followed by stepwise addition of MeCN with POCl3 and ammonia, produced the desired sulfonamide (II) in 61% yield. The latter showed serotonin re-uptake inhibition (SRI) activity with IC50 ≤ 50 nM and was > 100-fold as potent in the inhibition of serotonin re-uptake than in the the inhibition of dopamine and noradrenaline re-uptake. I are useful in the treatment of disorders such as depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders, and sexual dysfunction, including premature ejaculation (no data).

IT **289717-37-9P 364323-82-0P 364323-83-1P 364323-84-2P 364323-85-3P 364323-86-4P 364323-87-5P 364323-88-6P 364323-89-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of di-Ph ether compds. as serotonin re-uptake inhibitors)

RN 289717-37-9 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364323-82-0 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-83-1 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364323-84-2 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-85-3 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[3-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-86-4 HCAPLUS
CN Benzenemethanamine, 2-(4-bromophenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 364323-87-5 HCAPLUS

CN Benzenemethanamine, N-methyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-88-6 HCAPLUS
CN Benzenemethanamine, N-methyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-89-7 HCAPLUS
CN Benzenemethanamine, 2-[4-(ethylthio)phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **364321-43-7P 364321-47-1P 364321-48-2P**
364321-49-3P 364321-52-8P 364321-53-9P
364321-54-0P 364321-56-2P 364321-57-3P
364321-58-4P 364321-59-5P 364321-61-9P
364321-62-0P 364321-64-2P 364321-65-3P
364321-66-4P 364321-67-5P 364321-68-6P
364321-70-0P 364322-28-1P 364322-29-2P
364322-33-8P 364322-34-9P 364322-35-0P
364322-36-1P 364322-37-2P 364322-59-8P
364322-60-1P 364322-61-2P 364322-95-2P
364322-96-3P 364322-97-4P 364322-98-5P
364323-48-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of di-Ph ether compds. as serotonin re-uptake inhibitors)

RN 364321-43-7 HCAPLUS

CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 364321-47-1 HCAPLUS

CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-48-2 HCAPLUS

CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-49-3 HCAPLUS

CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-52-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-53-9 HCAPLUS
CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-54-0 HCAPLUS
CN Benzenemethanamine, 5-methoxy-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



Searched by P. Ruppel

RN 364321-56-2 HCAPLUS
CN Benzenemethanamine, 5-iodo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-57-3 HCAPLUS
CN Benzenemethanamine, 5-iodo-N-methyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-58-4 HCAPLUS
CN Benzenemethanamine, 5-iodo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-59-5 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-5-nitro- (9CI) (CA INDEX NAME)



RN 364321-61-9 HCAPLUS
CN Benzenemethanamine, N-methyl-5-nitro-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-62-0 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-nitro-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-64-2 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-nitro-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 364321-65-3 HCAPLUS
CN Benzenemethanamine, 5-bromo-N-methyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-66-4 HCAPLUS
CN Benzenemethanamine, 4-bromo-N-methyl-2-[4-(trifluoromethoxy)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-67-5 HCAPLUS
CN Benzenemethanamine, 5-methoxy-N-methyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-68-6 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-[3-methoxy-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 364321-70-0 HCAPLUS
CN Benzenemethanamine, 5-bromo-N-methyl-2-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-28-1 HCAPLUS
CN Benzenesulfonamide, 2-bromo-5-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-29-2 HCAPLUS
CN Benzenesulfonamide, 5-[(methylamino)methyl]-2-(methylthio)-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-33-8 HCAPLUS
CN Benzonitrile, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-34-9 HCAPLUS
CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-35-0 HCAPLUS
CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-36-1 HCAPLUS
CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI)

(CA INDEX NAME)



RN 364322-37-2 HCAPLUS
CN Benzonitrile, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-59-8 HCAPLUS
CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-60-1 HCAPLUS
CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-61-2 HCAPLUS

CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-95-2 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-(methylthio)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-96-3 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(methylthio)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-97-4 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-(methylthio)-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-98-5 HCAPLUS
CN Benzenemethanamine, 4-(ethylthio)-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-48-8 HCAPLUS
CN Benzenemethanamine, 5-chloro-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



IT **364321-41-5P 364321-44-8P 364321-45-9P**
364321-50-6P 364321-51-7P 364321-55-1P
364322-30-5P 364322-31-6P 364322-32-7P
364322-38-3P 364322-89-4P 364322-99-6P
364323-00-2P 364323-01-3P 364323-02-4P
364323-04-6P 364323-05-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di-Ph ether compds. as serotonin re-uptake inhibitors)
RN 364321-41-5 HCAPLUS
CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-44-8 HCAPLUS
CN Benzenemethanamine, 5-fluoro-N-methyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-45-9 HCAPLUS
CN Benzenemethanamine, N-ethyl-5-fluoro-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-50-6 HCAPLUS
CN Benzenemethanamine, 5-fluoro-N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-51-7 HCAPLUS
CN Benzenemethanamine, 4-bromo-N-methyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-55-1 HCAPLUS
CN Benzenemethanamine, 4,5-dimethoxy-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-30-5 HCAPLUS
CN Benzenesulfonamide, 2-bromo-5-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-31-6 HCAPLUS
CN Benzenesulfonamide, 5-[(dimethylamino)methyl]-2-(methylthio)-4-[4-(trifluoromethoxy)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364322-32-7 HCAPLUS
CN Benzonitrile, 3-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-38-3 HCAPLUS
CN Benzonitrile, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-89-4 HCAPLUS
CN Benzenemethanamine, 5-chloro-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-99-6 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-00-2 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfinyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 364323-01-3 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfinyl)-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-02-4 HCAPLUS
CN Benzenemethanamine, 4-(ethylsulfinyl)-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-04-6 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(methylsulfinyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-05-7 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(methylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 18 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:693325 HCAPLUS
DOCUMENT NUMBER: 135:257243
TITLE: Preparation of condensed imidazoles as histamine H3

receptor ligands

INVENTOR(S): Andersen, Knud Erik; Doerwald, Florencio Zaragoza; Sidelmann, Ulla Grove; Rudolf, Klaus; Stenkamp, Dirk; Hurnaus, Rudolf; Mueller, Stephan Georg; Krist, Bernd; Eriksen, Birgitte; Pesche, Bernd

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim International G.m.b.H.

SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068652	A1	20010920	WO 2001-DK188	20010316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002058659	A1	20020516	US 2001-810237	20010316
US 6437147	B2	20020820		
EP 1268484	A1	20030102	EP 2001-916934	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003527395	T2	20030916	JP 2001-567743	20010316
US 2003135056	A1	20030717	US 2002-201865	20020723

PRIORITY APPLN. INFO.:

DK 2000-441	A	20000317
DK 2000-1016	A	20000629
US 2000-193741P	P	20000331
US 2000-216553P	P	20000707
US 2001-810237	A1	20010316
WO 2001-DK188	W	20010316

OTHER SOURCE(S): MARPAT 135:257243

GI



I

AB A novel class of imidazo heterocyclic compds. (shown as I (e.g. 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid [(1S)-(naphth-1-

yl)ethyl]amide) as well as any optical or geometric isomer or tautomeric form thereof including mixts. of these or a pharmaceutically acceptable salt thereof), pharmaceutical compns. comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. In I: R1 is H or a functional group, which can be converted to H in vivo. R2 is H, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, halogen, cyano, trifluoromethyl, hydroxy, thiol or amino. R3 and R4 independently are H or C1-6-alkyl, which is optionally substituted with aryl or heteroaryl, which are optionally substituted with one or more substituents selected from nitro, -NR7R8, -S(O)2NR7R8, -C(O)NR7R8, hydroxy, halogen, cyano, trifluoromethyl, -OCF3, -OCHF2, -OCH2CHF2, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkylsulfonyl, -C(O)OR7, C1-6-alkylcarbonyl, -C(:NOR7)C1-6-alkyl, C3-10-cycloalkyl, C3-10-cycloalkylcarbonyl, -C(:NOR7)C3-10-cycloalkyl, aryl-C1-6-alkyl, heteroaryl-C1 6-alkyl, arylamino, heteroarylamino, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, -C(:NOR7)aryl, -C(:NOR7)heteroaryl, arylthio, heteroarylthio, aryloxy and heteroaryloxy. R7 and R8 independently are H or C1-6-alkyl. M is 0-2; n is 1-4; X is a valence bond, -O-, -S-, -S(O)-, -S(O)2- or -CF2-; p is 0-3; Y is valence bond, -O-, -S-, or -NR9-, wherein R9 is H or C1-6-alkyl; V is :O, :S, :NR10 (R10 = H, cyano, nitro, C1-6-alkyl); W is valence bond, -O-, -S-, -NR11- (R11 = H, C1-6-alkyl); q is 0-3. Z is heteroaryl, aryl, aryloxy, C3-10-cycloalkyl, C3-8-heterocyclyl or aryl annulated with C3-8-heterocyclyl, C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl, which are optionally substituted with various provisos. More particularly, the compds. are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. The claimed compds. generally show a high binding affinity to the histamine H3 receptor, most preferably IC50 < 500 nM. Ninety-two example prepns. are included, but the methods of preparation are not claimed. Pharmaceutical compns. containing the compds. are claimed effective for reduction
of weight, suppression of appetite and treatment and/or prevention of eating disorders (e.g. bulimia, binge eating), impaired glucose tolerance (IGT), Type 2 diabetes, allergic rhinitis, ulcer, anorexia, diseases and disorders related to the serotonin-3 receptor (5-HT3; e.g. emesis), diseases and disorders related to the vanilloid receptor (e.g. pain, neurogenic inflammation, obesity), and diseases and disorders related to the alpha-2 adrenergic receptor (e.g. sleep inducing agent).

IT **361394-74-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of condensed imidazoles as histamine H3 receptor ligands)

RN 361394-74-3 HCAPLUS

CN Benzenemethanamine, N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)



IT **175136-89-7 361394-40-3**
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of condensed imidazoles as histamine H3 receptor ligands)

RN 175136-89-7 HCAPLUS
CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



RN 361394-40-3 HCAPLUS
CN Benzenemethanamine, 2-fluoro-6-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 19 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:396851 HCAPLUS
DOCUMENT NUMBER: 135:19652
TITLE: 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
INVENTOR(S): Adams, Jerry L.; Bower, Michael J.; Hall, Ralph F.; Griswold, Don E.; Underwood, David C.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038312	A1	20010531	WO 2000-US31861	20001121
W: AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1235814	A1	20020904	EP 2000-980569	20001121

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003514899 T2 20030422 JP 2001-540075 20001121
PRIORITY APPLN. INFO.: US 1999-166977P P 19991123
WO 2000-US31861 W 20001121
OTHER SOURCE(S): MARPAT 135:19652

GI



I



II

AB Novel substituted quinazoline compds. are disclosed, specifically I [R1 = (un)substituted Ph, naphthyl, heterocyclyl or heteroaryl; R2 = (un)substituted alkyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); X = O or S] and their pharmaceutically acceptable salts. Also disclosed are pharmaceutical compns. containing I, and use of I in therapy as CSBP/RK/p38 kinase inhibitors. Applications of I as such to a wide variety of arthritic, inflammatory, proliferative, and viral conditions are specifically claimed. Also claimed is use of I in conjunction with various other drugs or drug classes. Three examples of I were prepared and specifically claimed. For instance, 2,6-difluorobenzonitrile was coupled first with aniline using NaH in DMSO, and then with phenol using NaH in THF. The resulting 2-phenoxy-6-(phenylamino)benzonitrile underwent reduction of the nitrile to aminomethyl using LiAlH4, and the product underwent cyclocondensation with 1,1'-carbonyldiimidazole, to give title compound II. Representative compds. I had IC50 values < 50 μM in a CSBP/p38 kinase assay.

IT **342431-66-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of dihydroquinazolinones as CSBP/RK/p38 kinase inhibitors)

RN 342431-66-7 HCAPLUS

CN Benzenemethanamine, 2-amino-6-phenoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 20 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:283913 HCAPLUS
DOCUMENT NUMBER: 134:310974
TITLE: Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
INVENTOR(S): Howard, Harry Ralph, Jr.; Adam, Mavis Diane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027068	A1	20010419	WO 2000-IB1373	20000927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014733	A	20020611	BR 2000-14733	20000927
EP 1220831	A1	20020710	EP 2000-960916	20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511434	T2	20030325	JP 2001-530089	20000927
EE 200200191	A	20030616	EE 2002-191	20000927
US 6410736	B1	20020625	US 2000-692335	20001019
NO 2002001659	A	20020408	NO 2002-1659	20020408
BG 106603	A	20021229	BG 2002-106603	20020410
ZA 2002002804	A	20030410	ZA 2002-2804	20020410
HR 2002000324	A1	20030831	HR 2002-324	20020412
US 2003055038	A1	20030320	US 2002-153308	20020522
US 6596741	B2	20030722		

PRIORITY APPLN. INFO.:
US 1999-159276P P 19991013
US 1999-167761P P 19991129
WO 2000-IB1373 W 20000927
US 2000-692335 A3 20001019

OTHER SOURCE(S): MARPAT 134:310974
GI



I

AB The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered saturated (un)substituted ring containing 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F atoms; CR3R4 = 4-8 membered saturated (un)substituted carbocyclic ring; NR2CR3 = 4-8 membered saturated (un)substituted ring containing 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heteroaryl, heterocyclyl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.] and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prepared E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-Cl2] was given. All exemplified compds. I showed IC50 of ≤ 250 nM for serotonin reuptake inhibition, and IC50 of ≤ 1000 nM for dopamine and for norepinephrine reuptake inhibition.

IT **289717-61-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biaryl ether derivs. as monoamine reuptake inhibitors)

RN 289717-61-9 HCAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



IT **334980-91-5P 334980-95-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biaryl ether derivs. as monoamine reuptake inhibitors)
RN 334980-91-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl-5-nitro- (9CI) (CA INDEX NAME)



RN 334980-95-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-nitro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 21 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:790459 HCAPLUS
DOCUMENT NUMBER: 133:350040
TITLE: Preparation of agents for serotonin transporter SPECT imaging
INVENTOR(S): Kung, Hank F.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000066537	A1	20001109	WO 1999-US9344	19990430	
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9936712	A1	20001117	AU 1999-36712	19990430	
EP 1175388	A1	20020130	EP 1999-918906	19990430	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002543173	T2	20021217	JP 2000-615370	19990430	

PRIORITY APPLN. INFO.: WO 1999-US9344 A 19990430
OTHER SOURCE(S): MARPAT 133:350040
GI



I



II

AB Title compds. [I; A = H, Cl, Br, iodo, LR; L = bond, (CH2)n,(CH2)nCO; R = tetradentate ligand capable of chelating a metal(sic); R2 = H or Me; X = Cl, Br, iodo, NO2, NR3R4, LR; R3,R4 = H, OH, alkyl, alkanoyl, etc.; 1 of Y,Y' = CH2NR1Me and the other = H, NO2, CH2OR5, CH2NR1Me, NR3R4, LR; Z = S, O, NR6, CR7R8, CO, C(:CR7R8); R1,R5,R6 = H, LR, alkyl, alkanoyl, Ph, naphthyl, etc.; R7,R8 = H, Cl, alkyl; n = 1-5], with the proviso that 1 and only 1 of A,X,Y,R1,R3-R6 is LR or with the proviso that 1 or both of X or A is iodo, were prepared Data for biol. activity of I were given. E.g., 2,5-dibromobenzoic acid was coupled with freshly prepared 2-HSC6H4CONMe2 with sodium methoxide as the base to give the bromo-substituted diaryl sulfide; coupling with Bu3SnSnBu3 in the presence of a palladium catalyst followed by substitution of the tin with iodine to give IDAM II.

IT **305384-74-1**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of agents for serotonin transporter SPECT imaging)

RN 305384-74-1 HCAPLUS
CN Benzenemethanamine, 2-(4-iodophenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **291781-27-6P**
RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(preparation of agents for serotonin transporter SPECT imaging)
RN 291781-27-6 HCAPLUS
CN Benzenemethanol, 2-[2-[(dimethylamino)methyl]phenoxy]-5-iodo- (9CI) (CA INDEX NAME)



IT **291781-29-8P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of agents for serotonin transporter SPECT imaging)
RN 291781-29-8 HCAPLUS
CN Benzenemethanol, 2-[2-[(dimethylamino)methyl]phenoxy]-5-(iodo-125I)- (9CI) (CA INDEX NAME)



IT **291781-24-3P 291781-25-4P 291781-26-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of agents for serotonin transporter SPECT imaging)
RN 291781-24-3 HCAPLUS
CN Benzoic acid, 2-[2-[(dimethylamino)methyl]phenoxy]-5-nitro-, methyl ester

(9CI) (CA INDEX NAME)



RN 291781-25-4 HCAPLUS
CN Benzoic acid, 5-amino-2-[2-[(dimethylamino)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 291781-26-5 HCAPLUS
CN Benzenemethanol, 5-amino-2-[2-[(dimethylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 22 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:761658 HCAPLUS
DOCUMENT NUMBER: 134:162754
TITLE: Parallel solution-phase syntheses of functionalized bicyclo[2.2.2]octanes: generation of a library using orchestrated multi-step sequences of polymer-supported reagents and sequesterants

AUTHOR(S): Ley, Steven V.; Massi, Alessandro
CORPORATE SOURCE: Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
SOURCE: Perkin 1 (2000), (21), 3645-3654
CODEN: PERKF9; ISSN: 1470-4358
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:162754

AB An array of bicyclo[2.2.2]octane derivs. was prepared in high yield using an orchestrated multi-step sequence of polymer-supported reagents and sequestering agents, without any chromatog. purification steps. Nine intermediate libraries were synthesized, with the final library possessing five sites of diversity. Key steps included an efficient tandem Michael addition reaction of acrylates with cyclohexenones and a subsequent reductive amination reaction.

IT **175136-89-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(parallel solution-phase syntheses of functionalized bicyclo[2.2.2]octanes)

RN 175136-89-7 HCAPLUS
CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 23 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:608708 HCAPLUS
DOCUMENT NUMBER: 133:207665
TITLE: Preparation of phenoxybenzylamines as monoamine reuptake inhibitors
INVENTOR(S): Elliott, Mark Leonard; Howard, Harry Ralph, Jr.; Schmidt, Christopher Joseph; Seeger, Thomas Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050380	A1	20000831	WO 2000-IB108	20000202

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1154984	A1	20011121	EP 2000-900785	20000202	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 2000008958	A	20011127	BR 2000-8958	20000202	
EE 200100441	A	20021216	EE 2001-441	20000202	
AU 763884	B2	20030731	AU 2000-30709	20000202	
NZ 512910	A	20031128	NZ 2000-512910	20000202	
US 2002143003	A1	20021003	US 2001-845992	20010430	
US 6677378	B2	20040113			
HR 2001000585	A1	20021231	HR 2001-585	20010807	
NO 2001004047	A	20011022	NO 2001-4047	20010820	
ZA 2001006890	A	20020923	ZA 2001-6890	20010821	
BG 105858	A	20020430	BG 2001-105858	20010830	

PRIORITY APPLN. INFO.:	US 1999-121313P	P	19990223
	US 2000-529207	A2	20000202
	WO 2000-IB108	W	20000202

OTHER SOURCE(S): MARPAT 133:207665
GI



I

AB ROZCR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prepared as monoamine reuptake inhibitors (no data). Thus, 2,5-F(F3C)C6H3CHO was aroxylated by 3,4-Cl2C6H3OH and the product reductively aminated by Me2NH to give title compound I.

IT **146520-69-6P 146797-20-8P 289716-74-1P**
289716-75-2P 289716-79-6P 289716-80-9P
289716-82-1P 289716-85-4P 289716-88-7P
289716-89-8P 289716-91-2P 289716-92-3P
289716-93-4P 289716-94-5P 289716-95-6P
289716-96-7P 289716-97-8P 289716-98-9P
289717-00-6P 289717-01-7P 289717-02-8P
289717-04-0P 289717-06-2P 289717-08-4P
289717-09-5P 289717-11-9P 289717-13-1P
289717-15-3P 289717-16-4P 289717-17-5P
289717-18-6P 289717-19-7P 289717-23-3P
289717-24-4P 289717-25-5P 289717-26-6P
289717-28-8P 289717-29-9P 289717-30-2P

289717-32-4P 289717-33-5P 289717-34-6P
289717-35-7P 289717-36-8P 289717-37-9P
289717-38-0P 289717-39-1P 289717-41-5P
289717-42-6P 289717-43-7P 289717-44-8P
289717-45-9P 289717-46-0P 289717-47-1P
289717-48-2P 289717-49-3P 289717-50-6P
289717-51-7P 289717-52-8P 289717-53-9P
289717-54-0P 289717-55-1P 289717-56-2P
289717-57-3P 289717-58-4P 289717-59-5P
289717-60-8P 289717-61-9P 289717-62-0P
289717-63-1P 289717-64-2P 289717-65-3P
289717-66-4P 289717-67-5P 289717-68-6P
289717-69-7P 289717-70-0P 289717-71-1P
289717-72-2P 289717-73-3P 289717-74-4P
289717-75-5P 289719-21-7P 289719-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 146520-69-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 146797-20-8 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146797-19-5
CMF C15 H16 Cl N O





CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-74-1 HCAPLUS
CN Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289716-75-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- (9CI) (CA INDEX NAME)



RN 289716-79-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289716-80-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-79-6
CMF C16 H14 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-82-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-85-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (4:3) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-84-3
CMF C14 H13 Cl2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-88-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-ethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-87-6
CMF C15 H15 Cl2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-89-8 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-91-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-90-1
CMF C14 H14 Cl N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-92-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-94-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289716-95-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-94-5
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289716-96-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- (9CI) (CA INDEX NAME)



RN 289716-97-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-98-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-00-6 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-99-0
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-01-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-02-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-01-7
CMF C16 H14 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-04-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-difluorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-03-9
CMF C15 H15 F2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-06-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-difluorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-05-1
CMF C14 H13 F2 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-08-4 HCAPLUS
CN Benzenemethanamine, N,α-dimethyl-2-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-07-3
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-09-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 289717-11-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-10-8
CMF C15 H12 Cl2 F3 N O





CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-13-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-12-0
CMF C16 H18 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-15-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-14-2
CMF C16 H19 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-16-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 289717-17-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-16-4
CMF C15 H12 Cl2 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-18-6 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-19-7 HCAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-18-6
CMF C14 H12 Cl3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-23-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-24-4 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-25-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-24-4
CMF C15 H14 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-26-6 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-28-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-27-7
CMF C14 H12 Cl2 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-29-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-30-2 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-32-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-31-3
CMF C15 H15 Cl F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-33-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-34-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-35-7 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-36-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-37-9 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, hydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 289717-38-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-39-1 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-41-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-42-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-43-7 HCAPLUS
CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289717-44-8 HCAPLUS
CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-43-7
CMF C16 H18 F N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-45-9 HCAPLUS
CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-46-0 HCAPLUS
CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-47-1 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 289717-48-2 HCAPLUS
CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 289717-49-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, hydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 289717-50-6 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 289717-51-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-52-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-53-9 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,α-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-54-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-55-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-56-2 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,α-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-59-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 HCAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 HCAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-62-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-63-1 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-64-2 HCAPLUS
CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-65-3 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 HCAPLUS
CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 289717-67-5 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 289717-68-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,α-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-69-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)-

(9CI) (CA INDEX NAME)



RN 289717-70-0 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 HCAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 HCAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-73-3 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-74-4 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



Searched by P. Ruppel

RN 289717-75-5 HCAPLUS
CN Pyrrolidine, 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 289719-21-7 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289719-22-8 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **289718-11-2P**
RL: BYP (Byproduct); PREP (Preparation)
(preparation of phenoxybenzylamines as monoamine reuptake inhibitors)
RN 289718-11-2 HCAPLUS
CN Benzenemethanamine, 2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 24 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:255979 HCAPLUS
DOCUMENT NUMBER: 133:219564
TITLE: A novel serotonin transporter ligand: (5-Iodo-2-(2-dimethylaminomethylphenoxy)-benzyl alcohol
AUTHOR(S): Zhuang, Z.-P.; Choi, S.-R.; Hou, C.; Mu, M.; Kung, M.-P.; Acton, P. D.; Kung, H. F.
CORPORATE SOURCE: Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
SOURCE: Nuclear Medicine and Biology (2000), 27(2), 169-175
CODEN: NMBIEO; ISSN: 0969-8051
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The serotonin transporters (SERT) are the primary binding sites for selective serotonin reuptake inhibitors, commonly used antidepressants such as fluoxetine, sertraline, and paroxetine. Imaging of SERT with positron emission tomog. and single photon emission computed tomog. in humans would provide a useful tool for understanding how alterations of this system are related to depressive illnesses and other psychiatric disorders. In this article the synthesis and characterization of [125I]ODAM [(5-iodo-2-(2-dimethylaminomethylphenoxy)-benzyl alc.)] as an

imaging agent in the evaluation of central nervous system SERT are reported. In an initial binding study using cortical membrane homogenates of rat brain, ODAM displayed a good binding affinity with a value of Ki = 2.8 ± 0.88 nM. Using LLC-PK1 cells specifically expressing the individual transporter (i.e. dopamine [DAT], norepinephrine [NET], and SERT, resp.), ODAM showed a strong inhibition on SERT (Ki = 0.12 ± 0.02 nM). Inhibition consts. for the other two transporters were lower (Ki = 3.9 ± 0.7 μM and 20.0 ± 1.9 nM for DAT and NET, resp.). Initial biodistribution study in rats after an i.v. (IV) injection of [125I]ODAM showed a rapid brain uptake and washout (2.03, 1.49, 0.79, 0.27, and 0.07% dose/organ at 2, 30, 60, 120, and 240 min, resp.). The hypothalamus region where the serotonin neurons are located exhibited a high specific uptake. Ratios of hypothalamus-cerebellum/cerebellum based on percent dose per g of these two regions showed values of 0.35, 0.86, 0.86, 0.63, and 0.34 at 2, 30, 60, 120, and 240 min, post-IV injection, resp. The specific uptake in hypothalamus can be effectively blocked by pretreatment of known SERT ligands. The results suggest that this novel ligand displays desirable in vitro and in vivo properties as a potential SERT imaging agent.

IT **291781-29-8P**

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of radioiodinated iodo(dimethylaminomethylphenoxy)benzyl alc. as potential serotonin transporter imaging agent)

RN 291781-29-8 HCAPLUS

CN Benzenemethanol, 2-[2-[(dimethylamino)methyl]phenoxy]-5-(iodo-125I)- (9CI) (CA INDEX NAME)



IT **291781-24-3P 291781-25-4P 291781-26-5P 291781-27-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of radioiodinated iodo(dimethylaminomethylphenoxy)benzyl alc. as potential serotonin transporter imaging agent)

RN 291781-24-3 HCAPLUS

CN Benzoic acid, 2-[2-[(dimethylamino)methyl]phenoxy]-5-nitro-, methyl ester (9CI) (CA INDEX NAME)



RN 291781-25-4 HCAPLUS
CN Benzoic acid, 5-amino-2-[2-[(dimethylamino)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 291781-26-5 HCAPLUS
CN Benzenemethanol, 5-amino-2-[2-[(dimethylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 291781-27-6 HCAPLUS
CN Benzenemethanol, 2-[2-[(dimethylamino)methyl]phenoxy]-5-iodo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 25 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:618468 HCAPLUS
DOCUMENT NUMBER: 132:233682
TITLE: Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [123I]ODAM
AUTHOR(S): Acton, Paul D.; Mu, Mu; Plossl, Karl; Hou, Catherine; Siciliano, Michael; Zhuang, Zhi-Ping; Oya, Shunichi; Choi, Seok-Rye; Kung, Hank F.
CORPORATE SOURCE: Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA
SOURCE: European Journal of Nuclear Medicine (1999), 26(10), 1359-1362
CODEN: EJNMD9; ISSN: 0340-6997
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have described previously a selective serotonin transporter (SERT) radioligand, [123I]IDAM. We now report a similarly potent, but more stable IDAM derivative, 5-iodo-2-[2-[(dimethylamino)methyl]phenoxy]benzyl alc. ([123I]ODAM). The imaging characteristics of this radioligand were studied and compared against [123I]IDAM. Dynamic sequences of single-photon emission tomog. (SPET) scans were obtained on three female baboons after injection of 375 MBq of [123I]ODAM. Displacing doses (1 mg/kg) of the selective SERT ligand (+)McN5652 were administered 120 min after injection of [123I]ODAM. Total integrated brain uptake of [123I]ODAM was about 30% higher than [123I]IDAM. After 60-120 min, the regional distribution of tracer within the brain reflected the characteristic distribution of SERT. Peak specific binding in the midbrain occurred 120 min after injection, with an equilibrium midbrain to cerebellar ratio of 1.50±0.08, which was slightly lower than the value for [123I]IDAM (1.80± 0.13). Both the binding kinetics and the metabolism of [123I]ODAM were slower than those of [123I]IDAM. Following injection of a competing SERT ligand, (+)McN5652, the tracer exhibited washout from areas with high concns. of SERT, with a dissociation kinetic rate constant koff=0.0085±0.0028 min-1 in the midbrain. Similar studies using nisoxetine and methylphenidate showed no displacement, consistent with its low binding affinity to norepinephrine and dopamine transporters, resp. These results suggest that [123I]ODAM is suitable for selective SPET imaging of SERT in the primate brain, with higher uptake and slower kinetics and metabolism than [123I]IDAM, but also a slightly lower selectivity for SERT.

IT **262273-73-4**
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(SPET imaging of serotonin transporters in nonhuman primate brain with [123I]ODAM)

RN 262273-73-4 HCAPLUS
CN Benzenemethanol, 2-[2-[(dimethylamino)methyl]phenoxy]-5-(iodo-123I)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 26 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:113636 HCAPLUS
DOCUMENT NUMBER: 130:182255
TITLE: Preparation of aryloxyaniline derivatives as therapeutic agents with high affinity for the MDR receptors
INVENTOR(S): Nakazato, Atsuro; Okubo, Taketoshi; Nakamura, Toshio; Chaki, Shigeyuki; Tomisawa, Kazuyuki; Nagamine, Masashi; Yamamoto, Kenji; Harada, Koichiro; Yoshida, Masanori
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan; Nihon, Nohyaku Co., Ltd.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906353	A1	19990211	WO 1998-JP3442	19980803
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9884625	A1	19990222	AU 1998-84625	19980803
AU 729000	B2	20010125		
JP 11171844	A2	19990629	JP 1998-218784	19980803
EP 1004573	A1	20000531	EP 1998-935326	19980803
EP 1004573	B1	20021030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 226932	E	20021115	AT 1998-935326	19980803
PT 1004573	T	20030331	PT 1998-98935326	19980803
ES 2186186	T3	20030501	ES 1998-935326	19980803
US 6333358	B1	20011225	US 2000-485006	20000201
US 2002147191	A1	20021010	US 2001-922807	20010807
US 6476056	B2	20021105		

PRIORITY APPLN. INFO.: JP 1997-209123 A 19970804
WO 1998-JP3442 W 19980803
US 2000-485006 A3 20000201
OTHER SOURCE(S): MARPAT 130:182255
GI



I

AB The title compds. I [Ar1 and Ar2 represent each a substituted or unsubstituted Ph, pyridyl, or naphthyl group; R1 represents a hydrogen atom, an alkyl group or the like; X1 represents a hydrogen atom, an alkyl group or the like; and Y1 represents a branched or unbranched 1-6 C alkylene group or a single bond] are prepared I are useful in the treatment of anxiety and associated diseases, depression, and the like. In an in vitro test for affinity for the mitochondrial DBI receptors, the title compound I [Ar1Y1 = 3-methoxybenzyl; Ar2 = phenyl; R1 = methyl; X1 = H] showed IC50 of 1.38 nM.

IT **220553-21-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxyaniline derivs. as therapeutic agents with high affinity for the MDR receptors)

RN 220553-21-9 HCAPLUS

CN Acetamide, N-[2-[2-[(dimethylamino)methyl]phenoxy]phenyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 27 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:499172 HCAPLUS
DOCUMENT NUMBER: 127:176352
TITLE: Quinolin-2(1H)-ones as NMDA receptor antagonists
INVENTOR(S): Ackermann, Karl-august; Gottschlich, Rudolf; Holzemann, Gunter; Leibrock, Joachim; Rautenberg, Wilfried; Seyfried, Christoph
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany; Gottschlich, Rudolf; Holzemann, Gunter; Leibrock, Joachim; Rautenberg,

Wilfried; Seyfried, Christoph
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726244	A1	19970724	WO 1997-EP84	19970110
W: AU, BR, CA, CN, CZ, HU, JP, KR, LT, LV, MX, NO, PL, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19601782	A1	19970724	DE 1996-19601782	19960119
CA 2243474	AA	19970724	CA 1997-2243474	19970110
AU 9713112	A1	19970811	AU 1997-13112	19970110
AU 716230	B2	20000224		
EP 885196	A1	19981223	EP 1997-900586	19970110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1211974	A	19990324	CN 1997-192395	19970110
BR 9707027	A	19990720	BR 1997-7027	19970110
JP 2000503308	T2	20000321	JP 1997-525656	19970110
ZA 9700364	A	19970722	ZA 1997-364	19970116
NO 9803333	A	19980918	NO 1998-3333	19980717
US 6028080	A	20000222	US 1998-101837	19980717

PRIORITY APPLN. INFO.: DE 1996-19601782 A 19960119
WO 1997-EP84 W 19970110

OTHER SOURCE(S): MARPAT 127:176352
GI



I



II

AB Quinolinones I [R = substituted Ph; R1, R2 = H, halogen, alkyl, alkoxy] were prepared fo use in treating neurodegenerative disorders (no data). Thus, the quinolinone II and its enantiomers were obtained from 2-BrCH2COC6H4CH2CO2Me in 9 steps.

IT **193819-50-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylquinolinones as NMDA receptor antagonists)

RN 193819-50-0 HCAPLUS
CN Benzeneacetyl chloride, 3-[2-[(dimethylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



L51 ANSWER 28 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:151532 HCAPLUS
DOCUMENT NUMBER: 126:157822
TITLE: Synthesis of N-substituted oligomers as therapeutic agents
INVENTOR(S): Zuckermann, Ronald N.; Goff, Dane A.; Ng, Simon; Spear, Kerry; Scott, Barbara O.; Sigmund, Aaron C.; Goldsmith, Richard A.; Marlowe, Charles K.; Pei, Yazhong; Richter, Lutz; Simon, Reyna
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640202	A1	19961219	WO 1996-US8832	19960604
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
US 5877278	A	19990302	US 1995-487282	19950607
AU 9662534	A1	19961230	AU 1996-62534	19960604
EP 789577	A1	19970820	EP 1996-921278	19960604
EP 789577	B1	20030312		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 11507049	T2	19990622	JP 1996-501317	19960604
AT 234268	E	20030315	AT 1996-921278	19960604

PRIORITY APPLN. INFO.:
US 1995-487282 A 19950607
US 1992-950853 B2 19920924
US 1993-126539 B2 19930924
US 1994-277228 B2 19940718
WO 1996-US8832 W 19960604

AB The title process comprises a solid-phase method for synthesis of N-substituted oligomers, e.g., poly(N-substituted glycines) having a wide variety of side-chain substituents, to obtain compds. of potential

therapeutic interest. Each N-substituted glycine monomer is assembled from two sub-monomers directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a support-bound amine with an acylating agent containing a group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group with a second submonomer such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. Combinatorial libraries are disclosed.

IT **186700-05-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of N-substituted oligomers as therapeutic agents)
RN 186700-05-0 HCAPLUS
CN Benzenemethanamine, 2-(3-chlorophenoxy)- (9CI) (CA INDEX NAME)



L51 ANSWER 29 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:148791 HCAPLUS
DOCUMENT NUMBER: 126:157515
TITLE: Preparation of ortho-substituted aromatic compounds, containing three (het)aryl moieties as prostaglandin E2-(PGE2)-antagonists
INVENTOR(S): Breault, Gloria Anne; Oldfield, John; Tucker, Howard; Warner, Peter
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: Eur. Pat. Appl., 62 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 752421	A1	19970108	EP 1996-304888	19960702
R: CH, DE, FR, GB, IT, LI				
US 5834468	A	19981110	US 1996-673878	19960702
JP 09040607	A2	19970210	JP 1996-173990	19960703
US 6057345	A	20000502	US 1998-183578	19981030
US 2003139418	A1	20030724	US 2002-284610	20021031

PRIORITY APPLN. INFO.:

GB 1995-13900	A	19950707
GB 1995-13902	A	19950707
GB 1995-13903	A	19950707
GB 1995-13923	A	19950707
GB 1995-13924	A	19950707
GB 1995-13927	A	19950707
US 1996-673878	A3	19960702

US 1998-183578 A3 19981030
US 2000-505969 B1 20000217
US 2001-811779 B1 20010319

OTHER SOURCE(S): MARPAT 126:157515
GI



AB The title compds. [I; A = (un)substituted Ph, naphthyl, pyridazinyl, etc., and the -ZBR1 and -XD linking groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the -X- linking group (and therefore in the 3-position relative to the -Z- linking group) is not substituted; B = (un)substituted Ph, pyridyl, thiazolyl, etc.; D = (un)substituted pyridyl, pyrazinyl, pyrimidinyl, etc.; R1 = COOH, tetrazolyl, etc., and is positioned on ring B in a 1,3 or 1,4 relationship with the -Z- linking group in 6-membered rings and in a 1,3-relationship with the -Z- linking group in 5-membered rings; X = OCH2, SCH2, CH2CH2, etc.; Z = CH(R3)CH(R3)N(R2), N(R2)CH(R3), etc. (wherein R2 = H, C1-6 alkyl, C2-6 alkenyl, etc.; R3 = H, C1-4 alkyl)] were prepared Thus, reaction of 5-bromo-2-(phenethyl)benzaldehyde with Me 4-aminobenzoate followed by treatment of the intermediate with NaBH4, and hydrolysis of the resulting Me 4-{N-[5-bromo-2-(phenethyl)benzyl]amino}benzoate with 2N aqueous NaOH in MeOH/THF afforded the title compound II. Compds. I are useful in the treatment of pain such as the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), postoperative pain, post-partum pain, the pain associated with dental conditions (such as dental caries and gingivitis), the pain associated with burns (including sunburn), the treatment of bone disorders (such as osteoporosis, hypercalcemia of malignancy and Paget's disease), the pain associated with sports injuries and sprains and all other painful conditions in which E-type prostaglandins wholly or in part play a pathophysiol. role. In general, compds. I are effective at 0.05-25 mg/kg/day.

IT **186797-05-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ortho-substituted aromatic compds. containing three (het)aryl
moieties as prostaglandin E2-(PGE2)-antagonists)

RN 186797-05-7 HCAPLUS
CN Benzenemethanamine, N-ethyl-2-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 30 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:44662 HCAPLUS
DOCUMENT NUMBER: 126:59751
TITLE: Preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors
INVENTOR(S): Baker, William R.; Rosenberg, Saul H.; Fung, K. L. Anthony; Rockway, Todd W.; Fakhoury, Stephen A.; Garvey, David S.; Donner, B. Gregory; O'Connor, Stephen J.; Prasad, Rajnandan N.; Shen, Wang; Stout, David M.; Sullivan, Gerard M.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 241 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634851	A1	19961107	WO 1996-US6193	19960502
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5783593	A	19980721	US 1996-633262	19960429
AU 9656731	A1	19961121	AU 1996-56731	19960502

PRIORITY APPLN. INFO.:
US 1995-429095 19950503
US 1996-633262 19960429
US 1993-147708 19931104
US 1994-289711 19940909
US 1994-322783 19941018
WO 1996-US6193 19960502

OTHER SOURCE(S): MARPAT 126:59751
GI



I II

AB Title compds. [e.g., I; A1 = ZCONR1R2; A2,A4, and A5 or A2 and A4 or A3and

A4 = (protected) CO2H and the other An = H; R1 = (chloro)benzyl, (CH2)2-4Ph, CH2C6H4(OPh)-4; R2 = (CH2)1-2C6H4(OPh)-4; Z = bond, NR, O; R = H, (cyclo)alkyl, aralkyl, cycloalkylalkyl] were prepared Thus, 4-(PhO)C6H4CHO was reductively aminated by H2CH2Ph and the product amidated by 1,2,4,5-benzenetetracarboxylic dianhydride to give title compound II. Data for in vitro inhibition of protein farnesyltransferase by selected I were given.

IT **107624-14-6**, Benzenemethanamine, 2-phenoxy-
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors)

RN 107624-14-6 HCAPLUS

CN Benzenemethanamine, 2-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 31 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:191327 HCAPLUS

DOCUMENT NUMBER: 118:191327

TITLE: Preparation of (aminomethylphenoxy)halobenzenes and related compounds as antidepressants

INVENTOR(S): Ruigt, Gerardus Stephanus Franciscus; Leysen, Dirk; Wieringa, Johannes Hubertus

PATENT ASSIGNEE(S): AKZO N. V., Neth.

SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 516234	A1	19921202	EP 1992-201484	19920525
EP 516234	B1	19950913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
ZA 9203283	A	19930127	ZA 1992-3283	19920506
CA 2068373	AA	19921130	CA 1992-2068373	19920511
AU 9217104	A1	19921203	AU 1992-17104	19920522
AU 650136	B2	19940609		
ES 2079783	T3	19960116	ES 1992-201484	19920525
NO 9202110	A	19921130	NO 1992-2110	19920527
NO 178395	B	19951211		
NO 178395	C	19960320		
JP 05148197	A2	19930615	JP 1992-137276	19920528
US 5190965	A	19930302	US 1992-891545	19920529
US 5430063	A	19950704	US 1993-12700	19930203

PRIORITY APPLN. INFO.: EP 1991-201288 19910529
US 1992-891545 19920529

OTHER SOURCE(S): MARPAT 118:191327

GI



I

AB Title compds. I (R = 1 or 2 halo; A = R2R1NCH2 wherein R1, R2 = H, alkyl, 4,5-dihydro-1H-imidazolyl), were prepared 4-ClC6H4OH, NaH, 18-crown-6, and 2-BrC6H4CN were heated in DMF at 100° for 16 h to give 2-(4-ClC6H4O)C6H4CN which was treated with LiAlH4 in THF to give I (R = 4-Cl, A = CH2H2N.HCl (II). The 1/2 life of II in rats was 1-2.5 h.

IT **146797-18-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 146797-18-4 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-(3,4-dichlorophenoxy)benzenemethanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 146797-17-3
CMF C13 H11 Cl2 N O



CM 2

CRN 130-85-8
CMF C23 H16 O6



IT **146520-68-5P 146520-69-6P 146797-20-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antidepressant)

RN 146520-68-5 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 146520-69-6 HCAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 146797-20-8 HCAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, (2Z)-2-butenedioate

(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146797-19-5
CMF C15 H16 Cl N O





CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L51 ANSWER 32 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:75271 HCAPLUS
DOCUMENT NUMBER: 108:75271
TITLE: Synthesis of 2-phenylthiazolidine derivatives as cardiotonic agents. I. 2-Phenylthiazolidine-3-thiocarboxamides
AUTHOR(S): Nate, Hiroyuki; Sekine, Yasuo; Honma, Yasushi; Nakai, Hideo; Wada, Hiroshi; Takeda, Mikio; Yabana, Hideo; Nagao, Taku
CORPORATE SOURCE: Org. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd., Toda, 335, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1987), 35(5), 1953-68
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:75271
GI



AB Novel 2-phenylthiazoldine-3-thiocarboxamides I (R = 2-, 3-, 4-Cl, Me, OMe; 2-Me, 2-Et, 2-Pr, 2-Bu, 2-CH2NMe2, 2-NMe2, 2-OH, 2-OCH2Ph, 2-OCH2CO2H, 2-NHCOMe, 2-phenylpiperazinopropoxy etc.) was synthesized and tested for pos. inotropic activity in the isolated guinea pig heart and in anesthetized dogs. Reaction of RC6H4CHO with cysteamine followed by treatment with isothiocyanates readily gave I. Structure-activity relationships were investigated by varying the structural parameters. I (R = 2-Me, 2-OMe) exhibited significant pos. inotropic action, which was not blocked by propranolol. o-Alkoxyphenyl derivative II exhibited more potent and longer-lasting activity than amrinone without any significant effect on heart rate or blood pressure.

IT **112562-40-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and inotropic activity of)

RN 112562-40-0 HCAPLUS

CN 3-Thiazolidinecarbothioamide, N-methyl-2-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L51 ANSWER 33 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1985:406319 HCAPLUS

DOCUMENT NUMBER: 103:6319

TITLE: A new method of synthesizing 8-10-membered heterocyclic systems condensed with two aromatic rings

AUTHOR(S): Glinka, Ryszard; Piatowska, Elzbieta

CORPORATE SOURCE: Inst. Chem. Technol. Drugs, Sch. Med., Lodz, 90145, Pol.

SOURCE: Polish Journal of Chemistry (1984), 58(1-2-3), 259-62
CODEN: PJCHDQ; ISSN: 0137-5083

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:6319
GI



I



II

AB The diaminodiphenyl ether derivs I (m = 0, 1, n = p = 0; m = n = 0, p = 1, m = n = 1, p = 0) were treated with CS2 in pyridine contg iodine to give the macrocyclic derivs II.

IT **30293-17-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, with carbon disulfide heterocyclic derivs. from)

RN 30293-17-5 HCAPLUS

CN Benzenemethanamine, 2-(2-aminophenoxy)- (9CI) (CA INDEX NAME)



L51 ANSWER 34 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:191848 HCAPLUS
DOCUMENT NUMBER: 100:191848
TITLE: Synthesis of N,N'-disubstituted derivatives of dibenzo[b,h]tetrahydro-1,4,6-oxadiazonine
AUTHOR(S): Glinka, Ryszard
CORPORATE SOURCE: Inst. Chem. Technol. Drugs, Sch. Med., Lodz, 90145, Pol.
SOURCE: Polish Journal of Chemistry (1983), Volume Date 1982, 56(7-8-9), 1139-44
CODEN: PJCHDQ; ISSN: 0137-5083
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:191848
GI



I



II



III

AB The dibenzoxadiazonine I (R = p-MeC6H4SO2 throughout) was prepared in 7 steps from o-MeC6H4OC6H4NO2-o via cyclization. of o-(RNNaCH2)C6H4OC6H4(NNaR)-o with BrCH2Br. The tetrabenzotriazocyclohexadecane II was similarly prepared from the diether III in 3 steps.

IT **89914-08-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

RN 89914-08-9 HCAPLUS

CN Benzenemethanamine, 2-(2-nitrophenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 35 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:616253 HCAPLUS
DOCUMENT NUMBER: 97:216253
TITLE: Tricyclic compounds
PATENT ASSIGNEE(S): AKZO N. V. , Neth.
SOURCE: Neth. Appl., 16 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8006955	A	19820716	NL 1980-6955	19801222
WO 8202199	A1	19820708	WO 1981-EP195	19811212
W: AU, DK, FI, HU, JP				
AU 8279341	A1	19820720	AU 1982-79341	19811212
AU 547599	B2	19851024		
EP 57777	A1	19820818	EP 1981-201362	19811212
EP 57777	B1	19841010		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 57502258	T2	19821223	JP 1982-500173	19811212
JP 02014350	B4	19900406		
HU 28460	O	19831228	HU 1982-110	19811212
HU 185195	B	19841228		
AT 9798	E	19841015	AT 1981-201362	19811212
US 4374133	A	19830215	US 1981-331303	19811216
ZA 8108782	A	19821124	ZA 1981-8782	19811218
ES 508218	A1	19830216	ES 1981-508218	19811221
CA 1174236	A1	19840911	CA 1981-392881	19811222
FI 74957	B	19871231	FI 1982-1944	19820601
FI 74957	C	19880411		
DK 8202724	A	19820708	DK 1982-2724	19820617
DK 151332	B	19871123		
DK 151332	C	19880606		

PRIORITY APPLN. INFO.: NL 1980-6955 19801222
EP 1981-201362 19811212
WO 1981-EP195 19811212

GI



I

AB Dibenzoazacycloalkanes I (X = O, S, NR5; R = H, alkyl, aralkyl, hydroxyalkyl, acyloxyalkyl; R1-R4 = H, OH, halogen, cyano, alkyl, alkoxy, alkylthio, OCH2O, CF3, acyloxy; R5 = H, alkyl; n = 0-2) were prepared for use as tranquilizers (no data). Thus O(C6H4CH2CO2H-2)2 was reduced to the diol, brominated, and treated with PhCH2NH2 to give I (R = CH2Ph, R1-R4 = H, X = O, n = 1) which was debenzylated on Pd-C.

IT **83507-05-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 83507-05-5 HCAPLUS

CN Benzenemethanamine, 2-[2-(2-bromoethyl)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L51 ANSWER 36 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1982:455432 HCAPLUS

DOCUMENT NUMBER: 97:55432

TITLE: Non-steroidal antiinflammatory agents. 7. Methanesulfonanilides. II

AUTHOR(S): Schroeder, Eberhard; Lehmann, Manfred; Rufer, Clemens; Boettcher, Irmgard

CORPORATE SOURCE: Forschungslab., Schering A.-G., Berlin, 1000/65, Fed. Rep. Ger.

SOURCE: European Journal of Medicinal Chemistry (1982), 17(2), 165-72
CODEN: EJMCA5; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 97:55432

GI



I



II



III



IV

Searched by P. Ruppel

AB Analogs of the potent antiinflammatory sulfonanilide I were prepared and tested to determine structure-activity relationships. Of the compds. obtained by replacing the O atom of the PhO group by a direct bond, (substituted) methylene, or carbonyl group, only II (R1 = H, 2-Cl, 2-, 3-, 4-F) from the last procedure were active. Modifying the MeSO2NH moiety caused loss of activity, but chloro- and fluoromethanesulfonates III (R2 = R4 = H, R3 = ClCH2SO2; R2 = H, 4-Cl, 4-F, R3 = F3CSO2, R4 = H) and Ac derivative III (R2 = H, R3 = MeSO2, R4 = Ac) were active. The Ph ring was replaced with cyclohexyl, naphthyl, and heterocyclic groups and only pyridyl analogs IV (2-, 4-pyridyl, Z = S; 3-pyridyl, Z = O) showed antiinflammatory activity comparable to that of I.

IT **82472-01-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and mesylation of)

RN 82472-01-3 HCAPLUS

CN 1H-Indene-5-methanamine, 2,3-dihydro-6-phenoxy- (9CI) (CA INDEX NAME)



L51 ANSWER 37 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1979:6244 HCAPLUS

DOCUMENT NUMBER: 90:6244

TITLE: Pyrrolidine derivatives

INVENTOR(S): Beregi, Laszlo; Hugon, Pierre; Duhault, Jacques; Boulanger, Michelle

PATENT ASSIGNEE(S): Science Union et Cie., Societe Francaise de Recherche Medicale, Fr.

SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2807623	A1	19780831	DE 1978-2807623	19780222
DE 2807623	C2	19820701		
GB 1561411	A	19800220	GB 1977-8096	19770225
US 4161529	A	19790717	US 1978-877601	19780214
CA 1101872	A1	19810526	CA 1978-297370	19780221
FR 2381753	A1	19780922	FR 1978-5005	19780222
FR 2381753	B1	19790713		
AT 7801289	A	19800715	AT 1978-1289	19780222
AU 7833552	A1	19790830	AU 1978-33552	19780223
BE 864312	A1	19780824	BE 1978-185474	19780224

NL 7802069	A	19780829	NL 1978-2069		19780224
JP 53105475	A2	19780913	JP 1978-20820		19780224
JP 55016577	B4	19800502			
ES 467286	A1	19781016	ES 1978-467286		19780224
DD 134088	C	19790207	DD 1978-203847		19780224
IN 147858	A	19800719	IN 1978-DE148		19780224
CH 631162	A	19820730	CH 1978-2058		19780224
ZA 7801100	A	19790131	ZA 1978-1100		19781218
PRIORITY APPLN. INFO.:			GB 1977-8096		19770225

GI



I



II

AB The phenoxyphenylpyrrolidines I [R = H, halogen, alkyl, alkoxy, CF3; R1 = H, C1-4 aliphatic group, HO(CH2)2, HO(CH2)3, HO2CCH2] and their salts were prepared for use in regulation of lipid metabolism (no data). Thus, 4-MeOC6H4OC6H4COCl reacted with valine Me ester to give 4-(4-MeOC6H4O)C6H4CONHCH(CO2Me)CHMe2, which was saponified and treated successively with Ac2O, CH2:CHCN, and NaOH to give 4-(4-MeOC6H4O)C6H4COCH2CH2CN. Hydrogenative cyclization of this compound gave II.

IT **68548-77-6P 68548-78-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 68548-77-6 HCAPLUS

CN Pyrrolidine, 2-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 68548-78-7 HCAPLUS

CN Pyrrolidine, 2-(2-phenoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 38 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1976:164745 HCAPLUS
DOCUMENT NUMBER: 84:164745
TITLE: Synthesis of 6,7-dihydrodibenz[b,g][1,5-oxazocin-5-ones
AUTHOR(S): Lieb, Folker; Eiter, Karl
CORPORATE SOURCE: Wiss. Hauptlab., Bayer A.-G., Leverkusen, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1976), (2), 203-7
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 84:164745
GI



I



II



III

AB Dibenzoxazocinones I (R = H, Cl, R1 = H) were prepared by brominating II (R2 = H), treating II (R2 = Br) with K phthalimide, hydrazinolysis of II (R2 = phthalimido), and cyclization of II (R2 = NH2) with base. I (R1 = H) were aminoalkylated to give I (R1 = CH2CH2NMe2). The dioxadiazacyclohexadecenedione III was prepared by treating 2-R3OCH2C6H4OC6H4CN-2 (R3 = H, Et) with H2SO4.

IT **59167-58-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 59167-58-7 HCAPLUS
CN Benzoic acid, 2-[2-(aminomethyl)phenoxy]-5-chloro-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 39 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:118784 HCAPLUS
DOCUMENT NUMBER: 82:118784
TITLE: Antiarrhythmic agents. 2-, 3-, and 4-Substituted benzylamines
AUTHOR(S): Remy, David C.; Van Saun, William A., Jr.; Engelhardt, Edward L.; Torchiana, Mary L.; Stone, Clement A.
CORPORATE SOURCE: Merck Sharp and Dohme Res. Lab., Rahway, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1975), 18(2), 142-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Of 29 title compds. prepared and tested for antiarrhythmic activity in dogs, 2-(p-methoxyphenylethynyl)benzylamine-HCl (I-HCl) [54737-55-2], α,α-dimethyl-4-(phenylethynyl)benzylamine-HCl (II-HCl) [38135-42-1], and α,α-dimethyl-4-phenethylbenzylamine-HCl (III-HCl) [38135-43-2] showed good activity. Many of the compds. are more active antiarrhythmic agents than quinidine [56-54-2] tested under similar conditions. Structure-activity relations are discussed.
IT **31963-35-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)
RN 31963-35-6 HCAPLUS
CN Benzenemethanamine, 2-phenoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 40 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:141251 HCAPLUS
DOCUMENT NUMBER: 74:141251
TITLE: Antiarrythmic o-phenoxybenzylamine
INVENTOR(S): Remy, David C.
PATENT ASSIGNEE(S): Merck and Co., Inc.
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2047677	A	19710408	DE 1970-2047677	19700928
NL 7013566	A	19710331	NL 1970-13566	19700914
GB 1287497	A	19720831	GB 1970-1287497	19700928
FR 2070095	A5	19710910	FR 1970-35195	19700929
FR 2070095	B1	19750418		

PRIORITY APPLN. INFO.: US 1969-862076 19690929
AB The title compound was prepared by reaction of o-BrC6H4CN with PhONa in MeOH in the presence of Cu to give o-NCC6H4OPh which was reduced with LiAlH4 in Et2O.
IT **31963-35-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31963-35-6 HCAPLUS
CN Benzenemethanamine, 2-phenoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L51 ANSWER 41 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:3381 HCAPLUS
DOCUMENT NUMBER: 74:3381
TITLE: Nucleophilic aromatic substitution by aminophenoxide ions
AUTHOR(S): Schramm, Juergen; Radlmann, Eduard; Lohwasser, Hermann; Nischk, Guenther
CORPORATE SOURCE: Org.-Wiss. Lab., Farbenfabriken Bayer A.-G., Dormagen/Rhein, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1970), 740, 169-79
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal

LANGUAGE: German
OTHER SOURCE(S): CASREACT 74:3381

AB Aromatic RCl activated by o-or (and) p-NO2 reacted with x-H2NC6H4OK (I) in Me2SO at room temperature to give x-H2NC6H4OR (II) (x = o-, m-, or p-position, R = C6H4NO2-p or o-, C6H3(NO2)Cl-4,2, C6H3(NO2)CF3-2,4, C6H3-(NO2)2-2,4], in some cases addnl. in minor amts. 2,4-R1(O2N)-C6H3OC6H4[NHC6H3(NO2)R1-4,2]-4 (R1 = H, Cl, NO2), and 4-HOC6H4NHC6H3(NO2)R1-4,2, if R1 = NO2. 6,3- and 3,4-Cl-(H2N)C6H3OK reacted similarly to give the II-analogs. II were hydrogenated over Raney Ni to give the corresponding diamines. Similarly, o- and p-ClC6H4CN and I gave the corresponding H2NC6H4OC6H4CN, which were hydrogenated as above. Dichloroaryl and -heteroaryl compds. and I gave the corresponding H2NC6H4OQOC6H4NH2 (Q = 3,4-pyridazinylene, 2,4-pyrimidinylene, 1,4-phthalazinylene, 1,3-C6H3NO2-6, 1,3-C6H2(NO2)Cl-6,4, or 4-C6H4SO2C6H4-4).

IT **30202-94-9P 30203-00-0P 30203-01-1P 30293-17-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 30202-94-9 HCAPLUS
CN Benzylamine, o-(p-aminophenoxy)- (8CI) (CA INDEX NAME)



RN 30203-00-0 HCAPLUS
CN Benzylamine, o-(o-aminophenoxy)-, monopicrate (8CI) (CA INDEX NAME)

CM 1

CRN 30293-17-5
CMF C13 H14 N2 O



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 30203-01-1 HCAPLUS
CN Benzylamine, o-(p-aminophenoxy)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 30293-17-5 HCAPLUS
CN Benzenemethanamine, 2-(2-aminophenoxy)- (9CI) (CA INDEX NAME)



L51 ANSWER 42 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:466188 HCAPLUS
DOCUMENT NUMBER: 73:66188
TITLE: Macro chelate rings. III. Syntheses and configurations of complexes of new ligands, 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)dipheny l ether and 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenylamine
AUTHOR(S): Okawa, Hisashi; Koyama, Hiroyuki; Inazu, Takahiko; Yoshino, Tamotsu
CORPORATE SOURCE: Fac. Sci., Kyushu Univ., Fukuoka, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1970), 43(6), 1729-33
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Two quadridentate chelating agents, 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenyl ether (I) and 4,4'-dimethyl-2,2'-

bis(salicylideneaminomethyl)diphenylamine (II), which may form metal complexes with a ten-membered chelate ring, were synthesized and their Co(II), Ni(II), Cu(II), and Zn(II) complexes prepared The configurations around the central divalent metal ion were explored on the basis of the absorption of the ligand field in a solution A tetrahedral configuration for Co(II) and Zn(II) complexes, and a pseudotetrahedral configuration for the Ni(II) and Cu complexes, were concluded.

IT **27996-12-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27996-12-9 HCAPLUS

CN Benzylamine, 2,2'-oxybis[5-methyl-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

L51 ANSWER 43 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1961:118547 HCAPLUS
DOCUMENT NUMBER: 55:118547
ORIGINAL REFERENCE NO.: 55:22321f-i,22322a-b
TITLE: The synthesis of esters of some amino acids having pharmacological importance. I. The synthesis of esters of piperidino carboxylic acids
AUTHOR(S): Matkovics, Bela; Foldeak, Sandor; Porszasz, Janos; Sipos, Gyorgy
CORPORATE SOURCE: Tudomanyegyetem, Szeged, Hung.
SOURCE: Acta Pharmaceutica Hungarica (1961), 31, 113-21
CODEN: APHGAO; ISSN: 0001-6659
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian

AB RCH2CO2R' (I), RCH2CH2CO2R' (II), BzOCH2CH2R (III), and AcOCHMeCH2R (IV) were prepared I were prepared by condensing ClCH2CO2R' with a secondary amine, II by boiling ClCH2CH2CO2R' with the amine, and III by the reaction of an amino alc. with BzCl. The following I were obtained (R, R', b.p.°/mm., m.p. of picrate, m.p. of HCl salt, and m.p. of methiodide are given): piperidino, Me, 69°/5, 115°, 214°, 163-4°; piperidino, Et, 68°/1, 122°, 117-17.5°, 160-60.3°; piperidino, Bu, 100-1°/4, 85°, -, 178°; piperidino, PhCH2, 134-5°/1, 137°, 133°, 91-6°; morpholino, Me, 77°/2, 143°, 150.5°, 147.5°; morpholino, Et, 86-7°/4, 163°, 181°, 132-3°; morpholino, Bu, 105.5-106°/3, -, 127-9°, 95-6°; morpholino, PhCH2, 164-5°/5, 143°, 149°, -; pyrrolidino, Me, 72-3°/8, 104°, -, 153°; pyrrolidino, Et,

59-60°/2, 119.5°, 133-3.5°, -; pyrrolidino, Bu, 81-2°/3, 109.5°, -, -; pyrrolidino, PhCH2, 134-5°/1, 159-60°, 139-40°, 156°. The following II were prepared (data as above): piperidino, Me, 72°/2, 164°, 189°, 147-8°; piperidino, Et, 102-3°/5, 131.5°, 169°, -; piperidino, Bu, 124-5°/6, 108-9°, 164.7°, -; piperidino, PhCH2, 149-50°/1, 113°, 193.5°, -; piperidino, Ph, 114-20°/3, -, 192-5°, -; piperidino, CPh3, 171°/1, -, 214°, -; morpholino, Me, 82°/2, 129°, 203°, 151°; morpholino, Et, 108°/6, 108°, 188-9°, -; morpholino, Bu, 131-2°/6, 150°, 173°, 115°; morpholino, PhCH2, 154°/1, 125°, 189-90°, -; pyrrolidino, Me, 76°/5, 147°, 128°, 166°; pyrrolidino, Et, 85°/6, 114°, 146°, -; pyrrolidino, Bu, 106-8°/5, 97°, 74-5°, 115°; pyrrolidino, PhCH2, 145-6°/3, 102°, 152°, 154°. IV (R =pyrrolidino) (V), b3 75°, picrate m. 111-12°, gave a hygroscopic HCl salt. III (R = piperidino) b2 141°; HCl salt m. 184°; methiodide m. 141.5°. The action of the compds. on blood pressure and on respiration was given. II (R = N-piperidino, R' = CPh3) and V had strong antinicotinic action. The effect of the piperidino and pyrrolidino propionates was increased by quaternization.

IT **103044-26-4**, Veratrylamine, 2,2'-oxybis[N,N-diethyl- (preparation of)

RN 103044-26-4 HCAPLUS

CN Veratrylamine, 2,2'-oxybis[N,N-diethyl- (6CI) (CA INDEX NAME)



L51 ANSWER 44 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1957:71530 HCAPLUS

DOCUMENT NUMBER: 51:71530

ORIGINAL REFERENCE NO.: 51:12942c-i,12943a-i,12944a-c

TITLE: Alkaloid studies. XVII. The structure of the cactus alkaloid pilocereine

AUTHOR(S): Djerassi, Carl; Figdor, S. K.; Bobbitt, J. M.; Markley, F. X.

CORPORATE SOURCE: Wayne State Univ., Detroit, MI

SOURCE: Journal of the American Chemical Society (1957), 79, 2203-10
CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 51, 8118d. Structure I (R = CH2CHMe2) was elucidated for the

cactus alkaloid pilocereine. I (8.5 g.) in 200 cc. MeOH-280 cc. Et2O treated 6 days at 0° with 2.2 g. distilled CH2N2, the mixture treated with an addnl. 2.2 g. CH2N2, kept 3 days at 0°, and evaporated and the residue recrystd. from hexane yielded 6.5 g. Me ether (II) of I, m. 92-105°, resolidified and m. 153-5° (all m.ps. were determined on a Kofler block). II, m. 153-5° (from EtOAc), was transformed to a 2nd crystalline form, m. 133-5°; the transformation was reversed by recrystn. from hexane. I (3.0 g.) in 100 cc. absolute EtOH treated with 3.6 g. MeCHN2 in 150 cc. Et2O, kept 24 hrs. at room temperature, treated with an addnl. 3.6 g. MeCHN2, refrigerated 6 days, and evaporated yielded 2.07 g. Et ether (III) of I, m. 90-5° and 152-3° (from hexane); 2nd crop, 0.32 g. Amberlite IRA-400 (HCl) (200 g.) treated with 500 cc. 50% aqueous NaOH, 2 l. H2O, and finally 250 g. NaHCO3 in saturated aqueous solution and washed with 12-16 l. H2O gave the bicarbonate salt IRA-400-HCO3 which was stored under distilled H2O. Styphnates and picrates in EtOH or Me2CO containing about 5% H2O passed dropwise over a column of IRA-400-HCO3, the column washed with 2 vols. 10% aqueous Me2CO, the Me2CO removed in vacuo, acid added, the aqueous solution washed with Et2O and basified with NH4OH, and the base isolated with Et2O gave the corresponding free amines. II (2.5 g.) in 100 cc. 10% H2SO4 made just alkaline with 2N NaOH, treated dropwise at room temperature with 250 cc. 2% aqueous KMnO4, allowed to stand overnight, acidified with H2SO4, and extracted continuously with Et2O, the residue from the extract treated with SOCl2 and then PhNH2, and the product chromatographed yielded 35 mg. iso-PrCONHPh and 10 mg. iso-BuCONHPh. I (5.0 g.) in 200 cc. dry Et2O added slowly with stirring to 1.5 l. liquid NH3 at -60° during 5 hrs., the mixture warmed during 3 hrs. to -30°, treated cautiously with NH4Cl and evaporated overnight, the residue partitioned between Et2O and 3% aqueous NaOH, the alkaline layer acidified with 40% H2SO4, washed with Et2O, basified with concentrated NH4OH, and extracted with Et2O, and the extract evaporated gave 2.46 g. phenolic basic oil (IV); the original Et2O layer extracted with 10% HCl, dried, and evaporated left only a small amount of nonphenolic, nonbasic oil which was discarded; the acid extract basified with NH4OH and extracted with Et2O gave 2.40 g. nonphenolic, basic, glassy material (V). V consisted mainly of isopilocereine (VI); dipicrate, m. 235-7° (from Me2CO). VI dipicrate (3.5 g.) treated with LiOH and the resulting free base treated with CH2N2 in Et2O-MeOH yielded 55% Me ether (VII) of VI, b0.005 180-90° (evaporatively distilled). In 1 run, a 75-mg. aliquot of V treated with 40 mg. picric acid yielded 70 mg. 1-isobutyl-2-methyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline (VIII) picrate, m. 150-1° (from MeOH). IV (0.26 g.) treated 6 days at 0° with CH2N2 in Et2O containing a small amount of MeOH and evaporated, the residue extracted with Et2O and washed with 3% aqueous NaOH, and the resulting oil (0.2 g.) chromatographed on 9 g. Al2O3 gave 0.155 g. 7-MeO derivative (IX) of VIII, nD25 1.5284; styphnate, m. 212-13°; picrate, m. 184-5°. I (5 g.) in 1.5 l. dry NH3 treated at -30° with 6 g. K, and the mixture worked up in the usual manner gave 1.79 g. V and 2.68 g. IV; the IV dissolved in Et2O, dried, and concentrated yielded 1.45 g. demethylisopilocereine (X), m. 177.5-78°. X (100 mg.) treated 2 days at 0° with excess CH2N2 in Et2O and evaporatively distilled yielded 81 mg. glass, the infrared

spectrum of which closely resembled that of VI; treatment with picric acid gave a small amount of VI picrate. X (210 mg.) in Et2O-MeOH treated 7 days with CH2N2 yielded 120 mg. VII. IV (300 mg.) treated 7 days at room temperature with 0.84 g. MeCHN2 in Et2O, washed with alkali, and treated with picric acid gave the picrate of the 7-EtO derivative of VIII, m. 151.5-2.5°. Natural IX (2.2 g.) oxidized with KMnO4 yielded 310 mg. m-hemipinic acid, characterized as the di-Me ester, m. 89.5-90°; iso-PrCO2H and iso-BuCO2H were identified as their anilides. IX (2.47 g.) and 10 cc. MeI kept overnight at room temperature, the resulting methiodide (5.17 g.) dissolved in a small amount of H2O, added to 120 cc. 50% aqueous KOH, and refluxed 2 hrs., and the product isolated in the usual manner yielded 2.05 g. 2,4,5-[iso-Bu(Me2N) CH](MeO)2C6H2CH:CH2 (XI), oil. XI (185 mg.) in glacial AcOH ozonized 0.5 hr. at 15° and steam distilled into dimedon in MeOH, and the mixture kept 24 hrs. at 0° gave 39 mg. CH2O derivative, m. 193-5°. XI (1.87 g.) in MeOH hydrogenated 1 hr. over 5% Pd-C yielded the 1-Et analog (XII) of XI. XII converted to the methiodide (3.94 g.) and boiled with 50% aqueous KOH yielded 1.06 g. neutral N-free oil, apparently 3,4,5-Et(MeO)2C6H2CH:CHCHMe2; a 90-mg. portion ozonized and steam distilled into acidified aqueous 2,4-(O2N)2C6H3NHNH2, extracted with C6H6, and chromatographed on Al2O3 yielded 20 mg. iso-PrCHO derivative, m. 181-2°. IX oxidized with KMnO4 in the same manner as I gave iso-PrCO2H and iso-BuCO2H. VII (104 mg.) in C6H6 treated 4.5 hrs. with 1 cc. MeI gave 153 mg. VII.2MeI, m. 191-4° (from hexane-Me2CO). VII.2MeI (150 mg.) in 5 cc. MeOH and 20 cc. H2O passed 4 times over IRA-400-OH resin, the column washed with 20 cc. 50% aqueous MeOH, and the residue from the eluates distilled yielded 89 mg. gummy methine, C33H50N2O4, b0.05, 170-5°; a 100-mg. sample ozonized in CHCl3 at -60° gave 55 mg. CH2O-dimedon derivative; a 500-mg. sample in EtOH hydrogenated 10 min. over Pd-C yielded 450 mg. reduced methine (XIII), b0.005 160° (bath temperature). XIII (130 mg.) in Et2O treated with MeI, the dimethiodide (180 mg.) decomposed by the ion exchange resin method, the resulting neutral olefin (76 mg.), b0.005 160-80° ozonized in CHCl3, at -60°, and the distillate passed into 2,4-(O2N)2C6H3NHNH2 solution yielded 44% 2,4-(O2N)2 C6H3NHN:CHCHMe2 (XIIIa). II (2.56 g.) treated with MeI, the II.MeI (3.9 g.), m. 137-50° (decomposition), powdered, added to 100 cc. refluxing 40% aqueous NaOH, and refluxed 2.5 hrs., a 160-mg. portion of the resulting methine 4,2,-5-R(MeO)[CH(NMe2)(CH2CHMe2)]C6H2OC6H(OME)2[CH(NMe2)(CH2CHMe2)]R-2,3,6,5 (XIV) (R = CH:CH2) (2.0 g.) ozonized in AcOH, and the mixture steam distilled into 2,4-(O2N)2C6H3NHNH2 gave only 47 mg. CH2O derivative XIV (R = CH:CH2) (1.9 g.) in 50 cc. 95% EtOH hydrogenated over 300 mg. 10% Pd-C, and the crude product (1.85 g.) recrystd. from MeCN gave 0.92 g. XIV (R = Et), m. 101.5-3.5°. XIV (R = Et) (1.21 g.) subjected to a 2nd stage Hofmann degradation gave 0.45 g. Me3N picrate, m. 206-10°, and 0.84 g. N-free degradation product which ozonized in EtOAc at -60° and worked up in the usual manner yielded only 3% XIIIa. XIV (R = Et) converted to the dimethiodide (1.72 g.) and subjected to a Hofmann degradation in the usual manner except that the compound was first dissolved in EtOH gave a substance, b0.005 155-70°, which appeared to be the di-CH(OEt)CH2CHMe2 analog (XV) of XIV (R = Et). II (1.98 g.) cleaved in the usual manner with 90 cc. Et2O, 600 cc. liquid NH3, and 2.5 g. K at -60° during 7 hrs. gave 1.30 g. nonphenolic basic and 0.67 g. phenolic basic fractions. The nonphenolic fractions dissolved in 20

cc. hexane and chromatographed on 80 g. Al2O3 (deactivated with 2.4 cc. 10% AcOH), giving 114 fractions, and fractions 20-46 (hexane up to 1:1 hexane-C6H6) treated with alc. picric acid gave 0.53 g. picrate of VIII, m. 152-3°; fractions 47-83 (1:1 hexane-C6H6 to 99:1 C6H6-Et2O) treated with alc. picric acid gave 0.196 g. IX picrate, m. 183-5°. Fractions 100-12 (9:1 C6H6-Et2O) gave similarly 10% picrate of the 8-OH derivative (XVI) of IX, m. 150-5°. XVI (73 mg.) (from the picrate) treated 10 days at 0° with CH2N2 in Et2O-MeOH and the product treated with alc. picric acid yielded the picrate of the 8-MeO analog (XVII) of XVI, m. 132-4°. Fractions 112-14 (Et2O and 9:1 Et2O-MeOH) gave a picrate, m. unsharply above 210°, which may represent dimeric material. The phenolic cleavage product (0.67 g.) and CH2N2 in MeOH-Et2O refrigerated 8 days yielded 0.43 g. picrate of IX, m. 181-4°; the mother liquors transformed to the free amine by the ion exchange method and chromatographed on deactivated Al2O3 gave 0.164 g. oil which treated with picric acid yielded 0.175 g. picrate of XVII. III (2.04 g.) in 80 cc. Et2O and 600 cc. liquid NH3 treated at -60° with 3.3 g. K and the mixture worked up after 24 hrs. gave 1.30 g. nonphenolic basic and 0.51 g. phenolic basic fractions. The nonphenolic portion chromatographed in the usual manner gave 0.576 g. VIII picrate, m. 151-3°, 0.227 g. picrate of the 7-EtO analog (XVIII) of IX, m. 152-3°, and 0.244 g. picrate of the 8-OH derivative of XVIII, m. 153-4°. The phenolic portion (0.51 g.) methylated in the usual manner and treated with picric acid gave 0.356 g. picrate of IX, m. 183-5°.

IT **115606-43-4**, Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-2-methoxy-4-vinylphenoxy]-α-isobutyl-N,N-dimethyl-6-vinyl-
117272-08-9, Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-4-ethyl-2-methoxyphenoxy]-6-ethyl-α-isobutyl-N,N-dimethyl-
(preparation of)

RN 115606-43-4 HCAPLUS

CN Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-2-methoxy-4-vinylphenoxy]-α-isobutyl-N,N-dimethyl-6-vinyl- (6CI) (CA INDEX NAME)



RN 117272-08-9 HCAPLUS

CN Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-4-ethyl-2-methoxyphenoxy]-6-ethyl-α-isobutyl-N,N-dimethyl- (6CI) (CA INDEX NAME)




```
=> b caold
FILE 'CAOLD' ENTERED AT 11:29:44 ON 11 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REGistRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d que l54 nos
L6                STR
L7                STR
L8                STR
L9   (      6520)SEA FILE=REGISTRY SSS FUL L6
L10  (       747)SEA FILE=REGISTRY SUB=L9 SSS FUL (L6 AND (L7 OR L8))
L11               STR
L12               STR
L13               STR
L14               STR
L15          544 SEA FILE=REGISTRY SUB=L10 SSS FUL (L6 AND L14 NOT (L11 OR L12
                 OR L13))
L17               STR
L20               STR
L46               STR
L47               STR
L48               STR
L50          273 SEA FILE=REGISTRY SUB=L15 SSS FUL (L17 AND (L20 OR L46 OR L47
                 OR L48))
L54            3 SEA FILE=CAOLD ABB=ON  PLU=ON  L50

=> d iall hitstr 1-3
```

L54 ANSWER 1 OF 3 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA55:22321e CAOLD
TITLE: synthesis and halomethylation of bis(3,4-dimethoxyphenyl) ether-reaction of halomethyl derivs. with secondary amines and pyridines
AUTHOR NAME: Matarasso-Tchiroukhine, Elisabeth
INDEX TERM: 786-19-6 101432-12-6 101432-17-1 101744-16-5 102015-72-5 102015-78-1 **103044-26-4** 108480-92-8 108480-93-9 **116378-59-7** 116572-03-3 116572-04-4 117042-78-1 117042-83-8
IT **103044-26-4 116378-59-7**
RN 103044-26-4 CAOLD
CN Veratrylamine, 2,2'-oxybis[N,N-diethyl- (6CI) (CA INDEX NAME)



RN 116378-59-7 CAOLD
CN Veratrylamine, 2,2'-oxybis[N,N-diethyl-, dipicrate (6CI) (CA INDEX NAME)

CM 1

CRN 103044-26-4
CMF C26 H40 N2 O5



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L54 ANSWER 2 OF 3 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA52:9005i CAOLD
TITLE: synthesis of guanidine compds. of diphenyl ether - (I), (II) synthesis of diphenyl ether aldehyde by the Sommelet reaction and expts. with methylguanidine derivs. (1)
AUTHOR NAME: Ito, Genzo
INDEX TERM: 67-36-7 500-78-7 3396-01-8 19434-34-5 22479-78-3
36881-42-2 62248-88-8 76838-41-0 76839-21-9 78725-47-0
82657-72-5 91955-44-1 92028-82-5 100394-74-9 100714-40-7
100724-23-0 100956-00-1 100970-01-2 101091-62-7 101097-62-5
101112-34-9 101868-83-1 102078-83-1 102309-41-1 105901-52-8
105901-53-9 106272-17-7 107558-81-6 107622-81-1
107624-15-7 107771-82-4 107774-30-1 107776-32-9
107921-04-0 107922-64-5 108125-78-6 108752-39-2 108758-94-7
108800-18-6 108874-34-6 108923-35-9 108955-35-7 108955-88-0
109017-27-8 109102-87-6 109125-85-1 109125-91-9 109125-92-0
109556-73-2 109592-53-2 109592-68-9 110533-52-3 110974-03-3
114281-51-5 119077-06-4 119438-84-5 123777-32-2 124111-89-3
125644-23-7 132624-85-2

IT **107624-15-7**
RN 107624-15-7 CAOLD
CN Benzylamine, o-phenoxy-, nitrate (6CI) (CA INDEX NAME)

CM 1

CRN 107624-14-6
CMF C13 H13 N O



CM 2

CRN 7697-37-2
CMF H N O3



L54 ANSWER 3 OF 3 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA51:12942c CAOLD
TITLE: alkaloid studies - (XVII) structure of the cactus alkaloid pilocereine
AUTHOR NAME: Djerassi, Carl; Figdor, S. K.; Bobbitt, J. M.; Markley, F. X.
INDEX TERM: 479-49-2 3300-36-5 3423-32-3 25181-15-1 91809-56-2 93146-43-1 94326-14-4 95282-34-1 96506-44-4 101745-56-6 101745-83-9 102032-23-5 102589-65-1 103404-48-4 105820-94-8 111979-41-0 112045-14-4 115604-83-6 **115606-43-4** 116571-90-5 **117272-08-9** 121233-16-7 124142-92-3 124515-45-3

IT **115606-43-4 117272-08-9**

RN 115606-43-4 CAOLD
CN Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-2-methoxy-4-vinylphenoxy]-α-isobutyl-N,N-dimethyl-6-vinyl- (6CI) (CA INDEX NAME)



RN 117272-08-9 CAOLD
CN Veratrylamine, 2-[5-(1-dimethylamino-3-methylbutyl)-4-ethyl-2-methoxyphenoxy]-6-ethyl-α-isobutyl-N,N-dimethyl- (6CI) (CA INDEX NAME)